1
|
Marchant A, Van Damme P, Plotkin S, Neels P, Cassetti MC, Cramer J, Gruber MF, Goldblatt D, King D, Hartig-Merkel W, Vandeputte J. Enabling the evaluation of COVID-19 vaccines with correlates of protection. Biologicals 2024; 85:101723. [PMID: 37976940 DOI: 10.1016/j.biologicals.2023.101723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 10/20/2023] [Accepted: 10/24/2023] [Indexed: 11/19/2023] Open
Abstract
In February 2023, a meeting about correlates of protection (CoPs) against COVID-19 was organized by the International Alliance for Biological Standardization, the European Plotkin Institute for Vaccinology, and Vaccinopolis. The meeting aimed at reviewing the evidence, drawing conclusions, and identifying knowledge gaps. Collection of evidence is not straightforward. Neutralizing antibodies correlate with protection and are used for immunobridging studies within and between vaccine platforms for approval of new COVID-19 vaccines. In preparation for the next pandemic, it is vital that rapidly authorized initial vaccines are available to perform immunobridging studies very early. Additional components of the immune response likely contribute to protection against symptomatic infection. Current evidence is strongest for T lymphocytes and binding antibodies. Further studies are needed to consolidate this evidence and define their potential role in the evaluation of vaccines. For evaluation of mucosal vaccines, identifying CoPs against infection and transmission is key; further research is needed to identify and standardize methods suitable for clinical studies. CoPs for broadly protective beta-coronavirus vaccines remain a critical area of research. The knowledge, expertise, and capacity exist to conduct clinical studies using different designs in different populations to discover and validate CoPs, facilitating and accelerating evaluation of novel vaccines/vaccination platforms.
Collapse
Affiliation(s)
- Arnaud Marchant
- Institute for Medical Immunology (IMI), European Plotkin Institute for Vaccinology (EPIV), Université libre de Bruxelles, 808 Route de Lennik, 1070, Brussels, Belgium.
| | - Pierre Van Damme
- Centre for the Evaluation of Vaccination, European Plotkin Institute for Vaccinology (EPIV), Vaccine & Infectious Disease Institute, University of Antwerp, Faculty of Medicine & Health Sciences, Vaccinopolis/University of Antwerp, Drie Eikenstraat 663, 2650, Edegem, Belgium.
| | - Stanley Plotkin
- University of Pennsylvania, 18902, Doylestown, Pennsylvania, United States.
| | - Pieter Neels
- International Alliance for Biological Standardization (IABS), Rue Mina-Audemars 3, 1204, Genève, Switzerland.
| | - Maria Cristina Cassetti
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), 20852, United States.
| | - Jakob Cramer
- Coalition for Epidemic Preparedness Innovations (CEPI), Gibbs Building, 215 Euston Rd, Bloomsbury, London, NW1 2BE, United Kingdom.
| | - Marion F Gruber
- International AIDS Vaccine Initiative (IAVI), 125 Broad Street, New York, NY, 10004, United States.
| | - David Goldblatt
- Infection, Immunity, and Inflammation Department, Great Ormond Street Institute of Child Health, University College London and Great Ormond Street Children's Hospital, NHS Foundation Trust, 30 Guilford Street, London, WC1N 1EH, United Kingdom.
| | - Deborah King
- Wellcome Trust, Gibbs Building, 215 Euston Road, Bloomsbury, London, NW1 2BE, United Kingdom.
| | - Wendy Hartig-Merkel
- P95 Epidemiology & Pharmacovigilance, Koning Leopold III Laan 1, 3001, Leuven, Belgium.
| | - Joris Vandeputte
- International Alliance for Biological Standardization (IABS), Rue Mina-Audemars 3, 1204, Genève, Switzerland.
| |
Collapse
|
2
|
Dublin S, Greenwood-Hickman MA, Karliner L, Hsu C, Coley RY, Colemon L, Carrasco A, King D, Grace A, Lee SJ, Walsh JME, Barrett T, Broussard J, Singh U, Idu A, Yaffe K, Boustani M, Barnes DE. The electronic health record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR) Brain Health Trial: Protocol for an embedded, pragmatic clinical trial of a low-cost dementia detection algorithm. Contemp Clin Trials 2023; 135:107356. [PMID: 37858616 DOI: 10.1016/j.cct.2023.107356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 09/26/2023] [Accepted: 10/15/2023] [Indexed: 10/21/2023]
Abstract
BACKGROUND About half of people living with dementia have not received a diagnosis, delaying access to treatment, education, and support. We previously developed a tool, eRADAR, which uses information in the electronic health record (EHR) to identify patients who may have undiagnosed dementia. This paper provides the protocol for an embedded, pragmatic clinical trial (ePCT) implementing eRADAR in two healthcare systems to determine whether an intervention using eRADAR increases dementia diagnosis rates and to examine the benefits and harms experienced by patients and other stakeholders. METHODS We will conduct an ePCT within an integrated healthcare system and replicate it in an urban academic medical center. At primary care clinics serving about 27,000 patients age 65 and above, we will randomize primary care providers (PCPs) to have their patients with high eRADAR scores receive targeted outreach (intervention) or usual care. Intervention patients will be offered a "brain health" assessment visit with a clinical research interventionist mirroring existing roles within the healthcare systems. The interventionist will make follow-up recommendations to PCPs and offer support to newly-diagnosed patients. Patients with high eRADAR scores in both study arms will be followed to identify new diagnoses of dementia in the EHR (primary outcome). Secondary outcomes include healthcare utilization from the EHR and patient, family member and clinician satisfaction assessed through surveys and interviews. CONCLUSION If this pragmatic trial is successful, the eRADAR tool and intervention could be adopted by other healthcare systems, potentially improving dementia detection, patient care and quality of life.
Collapse
Affiliation(s)
- Sascha Dublin
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Kaiser Permanente Bernard Tyson School of Medicine, Pasadena, CA, USA.
| | | | - Leah Karliner
- University of California, San Francisco, San Francisco, CA, USA
| | - Clarissa Hsu
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
| | - R Yates Coley
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA
| | - Leonardo Colemon
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
| | - Anna Carrasco
- University of California, San Francisco, San Francisco, CA, USA
| | - Deborah King
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
| | | | - Sei J Lee
- University of California, San Francisco, San Francisco, CA, USA
| | | | - Tyler Barrett
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
| | - Jia Broussard
- University of California, San Francisco, San Francisco, CA, USA
| | - Umesh Singh
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
| | - Abisola Idu
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
| | - Kristine Yaffe
- University of California, San Francisco, San Francisco, CA, USA
| | - Malaz Boustani
- Indiana University School of Medicine, Indianapolis, IN, USA
| | | |
Collapse
|
3
|
van Duijn J, Stieh D, Fernandez N, King D, Gilmour J, Tolboom J, Callewaert K, Willems W, Pau MG, De Rosa SC, McElrath MJ, Barouch DH, Hayes P. Mosaic HIV-1 vaccination induces anti-viral CD8 + T cell functionality in the phase 1/2a clinical trial APPROACH. J Virol 2023; 97:e0112623. [PMID: 37811993 PMCID: PMC10617392 DOI: 10.1128/jvi.01126-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Accepted: 08/28/2023] [Indexed: 10/10/2023] Open
Abstract
IMPORTANCE The functionality of CD8+ T cells against human immunodeficiency virus-1 (HIV-1) antigens is indicative of HIV-progression in both animal models and people living with HIV. It is, therefore, of interest to assess CD8+ T cell responses in a prophylactic vaccination setting, as this may be an important component of the immune system that inhibits HIV-1 replication. T cell responses induced by the adenovirus serotype 26 (Ad26) mosaic vaccine regimen were assessed previously by IFN-γ ELISpot and flow cytometric assays, yet these assays only measure cytokine production but not the capacity of CD8+ T cells to inhibit replication of HIV-1. In this study, we demonstrate direct anti-viral function of the clinical Ad26 mosaic vaccine regimen through ex vivo inhibition of replication of diverse clades of HIV-1 isolates in the participant's own CD4+ T cells.
Collapse
Affiliation(s)
| | - Daniel Stieh
- Janssen Vaccines & Prevention B.V., Leiden, the Netherlands
| | - Natalia Fernandez
- IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom
| | - Deborah King
- IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom
| | - Jill Gilmour
- IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom
| | - Jeroen Tolboom
- Janssen Vaccines & Prevention B.V., Leiden, the Netherlands
| | | | | | - Maria G. Pau
- Janssen Vaccines & Prevention B.V., Leiden, the Netherlands
| | - Stephen C. De Rosa
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - M. Juliana McElrath
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Dan H. Barouch
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Peter Hayes
- IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom
| |
Collapse
|
4
|
Brown E, Jr GAF, Shelton A, Johnson T, Chen C, Shaheen S, Holden TL, Dao VA, Bien JYE, King D, Vitzthum L, Kirilcuk N, Morris A, Kin C, Dawes A, Sheth V, Chang DT, Pollom E. A Technology-Informed Approach to Clinical Trial Equity. Int J Radiat Oncol Biol Phys 2023; 117:e8. [PMID: 37786184 DOI: 10.1016/j.ijrobp.2023.06.664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Despite efforts to increase participation of diverse communities in clinical trials, ethnic/racial minorities remain underrepresented. One such determinant may be lack of access to a comprehensive cancer center that conducts clinical research. Historically, our institution has had low accrual from rural regions further away from our cancer center, with Hispanic or Latino (HL) patients (pts) being especially underrepresented in our clinical research. In this study, we explored the impact of a clinical trial that allowed pts to receive chemotherapy (chemo) with their local oncologist. We hypothesize that allowing pts to receive chemo locally will lead to higher rates of enrollment from populations under-represented in clinical trials. MATERIALS/METHODS We conducted a study for pts with rectal cancer to undergo short-course radiation followed by 4 months of chemo with the option to pursue watch and wait if pts achieve a clinical complete response. Radiation was administered at our institution while pts could receive standard-of-care chemo closer to home with their local oncologist. For pts who received chemo locally, the research coordinator and co-investigators held video visits with the pts prior to each chemo infusion to review adverse events (AE), labs, and chemo dosing. We compared demographic data of pts on this trial with that of pts enrolled across all adult therapeutic oncologic clinical trials over the same time period at our institution. Distance to our institution was calculated based on pts' primary residence zip code. Protocol compliance with AE reporting for pts who received chemo locally was assessed by chart review. RESULTS Between May 2020 and January 2023, 24/35 enrolled pts completed both radiation and chemo on trial. 13/24 pts (54%) received chemo locally. Of the 24 pts, 16 were White (67%), 7 Asian (29%), 1 Native Hawaiian/ Pacific Islander (4%). Of all enrolled patients, 4 were HL (16.7%), compared to our institutional average of 16.5%. All enrolled HL pts received their chemo locally. The average distance traveled by non-HL pts from their home to our institution was 87.7 miles (range 5.1 - 308). In contrast, HL pts traveled an average of 147.8 miles (range 110 - 249), 68% further than their non-HL counterparts. There was 100% compliance with AE reporting among those pts who received their chemo locally. CONCLUSION Although the percentage of HL participation in our study was consistent with our institutional average, all HL pts enrolled on the trial received treatment locally and lived substantially further from our institution than non-HL. By allowing pts to receive this part of treatment locally, we provided pts who live further away an opportunity to engage in clinical research without the associated financial and time toxicities related with traveling for treatment. By decentralizing clinical trials and leveraging telemedicine, we can promote the participation of under-represented groups in clinical trials.
Collapse
Affiliation(s)
- E Brown
- Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA
| | - G A Fisher Jr
- Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
| | - A Shelton
- Department of Surgery, Stanford University School of Medicine, Palo Alto, CA
| | - T Johnson
- Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
| | - C Chen
- Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
| | - S Shaheen
- Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
| | - T L Holden
- Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
| | - V A Dao
- Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
| | - J Y E Bien
- Kaiser Permanente Santa Clara Medical Center, Santa Clara, CA
| | - D King
- Department of Medical Oncology/Hematology, Northwell Health Cancer Institute, New Hyde Park, NY
| | - L Vitzthum
- Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA
| | - N Kirilcuk
- Department of Surgery, Stanford University School of Medicine, Palo Alto, CA
| | - A Morris
- Department of Surgery, Stanford University School of Medicine, Palo Alto, CA
| | - C Kin
- Department of Surgery, Stanford University School of Medicine, Palo Alto, CA
| | - A Dawes
- Department of Surgery, Stanford University School of Medicine, Palo Alto, CA
| | - V Sheth
- Department of Radiology, Stanford University School of Medicine, Palo Alto, CA
| | - D T Chang
- Department of Radiation Oncology, Michigan Medicine, Ann Arbor, MI
| | - E Pollom
- Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA
| |
Collapse
|
5
|
Sidiqi BU, Nosrati JD, Wu V, Kobritz M, La Gamma N, Whelan RL, Parashar B, King D, Tchelebi L, Herman JM. The Prevalence and Management of Synchronous Prostate and Rectal Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e339. [PMID: 37785185 DOI: 10.1016/j.ijrobp.2023.06.2398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Synchronous prostate and rectal cancer is rare and guidelines for co-management are not well established. This case series explores the prevalence of synchronous diagnosis and different treatment paradigms to propose a standardized approach to management. MATERIALS/METHODS We retrospectively reviewed all radiation treatments between 1/2017 and 12/2022 for curative intent treatment to both prostate and rectal cancer. Synchronous was defined as rectal or prostate cancer diagnosed within a 6-month period of each other. We collected baseline characteristics and treatment paradigms including the sequencing of chemoradiation (CRT), chemotherapy (CT), prostate boost, and surgery. RESULTS There were 10 out of 2204 total treated patients with prostate or rectal primary noted to have a synchronous diagnosis (0.45%). Table 1 shows characteristics and treatment approach for all patients with 50% receiving CRT and 50% CT alone first. At a median FU of 21.4 months, 2 patients did not complete therapy due to patient choice and both had progression of disease (POD). After completion of CRT, 6 patients underwent rectal surgery with 2 pathological complete response, and 2 patients proceeded with a Watch and Wait approach with clinical complete response on MRI. Prostate boost was delivered equally as often pre-surgery as post-surgery with both SBRT, EBRT and Seed Implant used. There was no grade 3+ RT related toxicity in the patients who completed all therapy. CONCLUSION This series represents one of the largest synchronous prostate and rectal cancer cohorts treated with curative intent. Future collaborative work is needed to develop guidelines in the treatment of synchronous prostate and rectal cancers. Although a rare diagnosis, the heterogeneity of approaches has led us to propose a standardized approach to management of synchronous diagnosis with upfront chemotherapy followed by EBRT inclusive of prostate and rectum followed by boost via brachytherapy (SBRT in non-candidates).
Collapse
Affiliation(s)
- B U Sidiqi
- Department of Radiation Medicine, Northwell Health Cancer Institute, New Hyde Park, NY
| | - J D Nosrati
- Department of Radiation Medicine, Northwell Health Cancer Institute, New Hyde Park, NY
| | - V Wu
- Division of Medical Oncology/Hematology, Northwell Health Cancer Institute, New Hyde Park, NY
| | - M Kobritz
- Division of Surgery, Northwell Health Cancer Institute, New Hyde Park, NY
| | - N La Gamma
- Division of Surgery, Northwell Health Cancer Institute, New Hyde Park, NY
| | - R L Whelan
- Division of Surgery, Northwell Health Cancer Institute, New Hyde Park, NY
| | - B Parashar
- Department of Radiation Medicine, Northwell Health Cancer Institute, New Hyde Park, NY
| | - D King
- Department of Medical Oncology/Hematology, Northwell Health Cancer Institute, New Hyde Park, NY
| | - L Tchelebi
- Department of Radiation Medicine, Northwell Health Cancer Institute, New Hyde Park, NY
| | - J M Herman
- Department of Radiation Medicine, Northwell Health Cancer Institute, New Hyde Park, NY
| |
Collapse
|
6
|
King D. Oral health training for carers. Br Dent J 2023; 235:231-232. [PMID: 37620456 DOI: 10.1038/s41415-023-6240-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Accepted: 07/06/2023] [Indexed: 08/26/2023]
Affiliation(s)
- D King
- Bollington, Cheshire, United Kingdom.
| |
Collapse
|
7
|
Ford A, Hwang A, Mo AX, Baqar S, Touchette N, Deal C, King D, Earle K, Giersing B, Dull P, Hall BF. Meeting Summary: Global Vaccine and Immunization Research Forum, 2021. Vaccine 2023; 41:1799-1807. [PMID: 36803897 PMCID: PMC9938725 DOI: 10.1016/j.vaccine.2023.02.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 01/17/2023] [Accepted: 02/09/2023] [Indexed: 02/21/2023]
Abstract
The 2021 Global Vaccine and Immunization Research Forum highlighted the considerable advances and recent progress in research and development for vaccines and immunization, critically reviewed lessons learned from COVID-19 vaccine programs, and looked ahead to opportunities for this decade. For COVID-19, decades of investments in basic and translational research, new technology platforms, and vaccines targeting prototype pathogens enabled a rapid, global response. Unprecedented global coordination and partnership have played an essential role in creating and delivering COVID-19 vaccines. More improvement is needed in product attributes such as deliverability, and in equitable access to vaccines. Developments in other priority areas included: the halting of two human immunodeficiency virus vaccine trials due to lack of efficacy in preventing infection; promising efficacy results in Phase 2 trials of two tuberculosis vaccines; pilot implementation of the most advanced malaria vaccine candidate in three countries; trials of human papillomavirus vaccines given in single-dose regimens; and emergency use listing of a novel, oral poliomyelitis type 2 vaccine. More systematic, proactive approaches are being developed for fostering vaccine uptake and demand, aligning on priorities for investment by the public and private sectors, and accelerating policy making. Participants emphasized that addressing endemic disease is intertwined with emergency preparedness and pandemic response, so that advances in one area create opportunities in the other. In this decade, advances made in response to the COVID-19 pandemic should accelerate availability of vaccines for other diseases, contribute to preparedness for future pandemics, and help to achieve impact and equity under Immunization Agenda 2030.
Collapse
Key Words
- bcg, bacille calmette-guérin
- bnab, broadly neutralizing antibody
- cepi, coalition for epidemic preparedness innovations
- chim, controlled human infection model
- ecvp, evidence considerations for vaccine policy
- eua, emergency use authorization
- eul, emergency use listing
- gvap, global vaccine action plan
- gvirf, global vaccine and immunization research forum
- hiv, human immunodeficiency virus
- hpv, human papillomavirus
- ia2030, immunization agenda 2030
- mers, middle east respiratory syndrome
- nopv-2, novel oral poliomyelitis type 2 vaccine
- ppp, public–private partnership
- r&d, research and development
- sars, severe acute respiratory syndrome
- vips, vaccine innovation prioritisation strategy
Collapse
Affiliation(s)
- Andrew Ford
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 9825, Bethesda, MD 20892-9825, USA.
| | - Angela Hwang
- Angela Hwang Consulting, PO Box 6601, Albany, CA 94706, USA.
| | - Annie X. Mo
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 9825, Bethesda, MD 20892-9825, USA
| | - Shahida Baqar
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 9825, Bethesda, MD 20892-9825, USA.
| | - Nancy Touchette
- Office of Global Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
| | - Carolyn Deal
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 9825, Bethesda, MD 20892-9825, USA.
| | - Deborah King
- Infectious Disease Health Challenge - Prevention, Wellcome Trust, London NW1 2BE, United Kingdom.
| | - Kristen Earle
- Vaccine Development & Surveillance, Bill & Melinda Gates Foundation, PO Box 23350, Seattle, Washington 98102, USA.
| | - Birgitte Giersing
- Department of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
| | - Peter Dull
- Vaccine Development & Surveillance, Bill & Melinda Gates Foundation, PO Box 23350, Seattle, Washington 98102, USA.
| | - B. Fenton Hall
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 9825, Bethesda, MD 20892-9825, USA
| |
Collapse
|
8
|
Connolly E, Thomson K, King D, Schilling K, Ryan J, Grimison P, Zhou D, Zhang B, Strach M, Baker A, Sibbald T, Bhadri V. 115TiP MYTH Study: Methotrexate for AYA in the home: A study of safety, feasibility, patient acceptability and cost effectiveness of an ambulatory model for AYA osteosarcoma patients. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.101152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
9
|
Glass JE, Dorsey CN, Beatty T, Bobb JF, Wong ES, Palazzo L, King D, Mogk J, Stefanik-Guizlo K, Idu A, Key D, Fortney JC, Thomas R, McWethy AG, Caldeiro RM, Bradley KA. Study protocol for a factorial-randomized controlled trial evaluating the implementation, costs, effectiveness, and sustainment of digital therapeutics for substance use disorder in primary care (DIGITS Trial). Implement Sci 2023; 18:3. [PMID: 36726127 PMCID: PMC9893639 DOI: 10.1186/s13012-022-01258-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 12/22/2022] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND Experts recommend that treatment for substance use disorder (SUD) be integrated into primary care. The Digital Therapeutics for Opioids and Other SUD (DIGITS) Trial tests strategies for implementing reSET® and reSET-O®, which are prescription digital therapeutics for SUD and opioid use disorder, respectively, that include the community reinforcement approach, contingency management, and fluency training to reinforce concept mastery. This purpose of this trial is to test whether two implementation strategies improve implementation success (Aim 1) and achieve better population-level cost effectiveness (Aim 2) over a standard implementation approach. METHODS/DESIGN The DIGITS Trial is a hybrid type III cluster-randomized trial. It examines outcomes of implementation strategies, rather than studying clinical outcomes of a digital therapeutic. It includes 22 primary care clinics from a healthcare system in Washington State and patients with unhealthy substance use who visit clinics during an active implementation period (up to one year). Primary care clinics implemented reSET and reSET-O using a multifaceted implementation strategy previously used by clinical leaders to roll-out smartphone apps ("standard implementation" including discrete strategies such as clinician training, electronic health record tools). Clinics were randomized as 21 sites in a 2x2 factorial design to receive up to two added implementation strategies: (1) practice facilitation, and/or (2) health coaching. Outcome data are derived from electronic health records and logs of digital therapeutic usage. Aim 1's primary outcomes include reach of the digital therapeutics to patients and fidelity of patients' use of the digital therapeutics to clinical recommendations. Substance use and engagement in SUD care are additional outcomes. In Aim 2, population-level cost effectiveness analysis will inform the economic benefit of the implementation strategies compared to standard implementation. Implementation is monitored using formative evaluation, and sustainment will be studied for up to one year using qualitative and quantitative research methods. DISCUSSION The DIGITS Trial uses an experimental design to test whether implementation strategies increase and improve the delivery of digital therapeutics for SUDs when embedded in a large healthcare system. It will provide data on the potential benefits and cost-effectiveness of alternative implementation strategies. CLINICALTRIALS gov Identifier: NCT05160233 (Submitted 12/3/2021). https://clinicaltrials.gov/ct2/show/NCT05160233.
Collapse
Affiliation(s)
- Joseph E. Glass
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| | - Caitlin N. Dorsey
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| | - Tara Beatty
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| | - Jennifer F. Bobb
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| | - Edwin S. Wong
- grid.34477.330000000122986657Department of Health Systems and Population Health, School of Public Health, University of Washington, Box 351621, 3980 15th Ave. NE, Fourth Floor, Seattle, WA 98195 USA ,grid.418356.d0000 0004 0478 7015Department of Veterans Affairs, Health Services Research and Development, Center of Innovation, 1660 S Columbian Way, WA 98108 Seattle, USA
| | - Lorella Palazzo
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| | - Deborah King
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| | - Jessica Mogk
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| | - Kelsey Stefanik-Guizlo
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| | - Abisola Idu
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| | - Dustin Key
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| | - John C. Fortney
- grid.418356.d0000 0004 0478 7015Department of Veterans Affairs, Health Services Research and Development, Center of Innovation, 1660 S Columbian Way, WA 98108 Seattle, USA ,grid.34477.330000000122986657Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Box 356560, 1959 NE Pacific Street, Seattle, WA 98195 USA
| | - Rosemarie Thomas
- Kaiser Permanente Washington Mental Health & Wellness Services, 1200 SW 27th St, Renton, WA 98057 USA
| | - Angela Garza McWethy
- Kaiser Permanente Washington Mental Health & Wellness Services, 1200 SW 27th St, Renton, WA 98057 USA
| | - Ryan M. Caldeiro
- Kaiser Permanente Washington Mental Health & Wellness Services, 1200 SW 27th St, Renton, WA 98057 USA
| | - Katharine A. Bradley
- grid.488833.c0000 0004 0615 7519Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101 USA
| |
Collapse
|
10
|
Fernandez N, Hayes P, Makinde J, Hare J, King D, Xu R, Rehawi O, Mezzell AT, Kato L, Mugaba S, Serwanga J, Chemweno J, Nduati E, Price MA, Osier F, Ochsenbauer C, Yue L, Hunter E, Gilmour J. Assessment of a diverse panel of transmitted/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay. Front Immunol 2022; 13:1029029. [PMID: 36532063 PMCID: PMC9751811 DOI: 10.3389/fimmu.2022.1029029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 11/14/2022] [Indexed: 12/03/2022] Open
Abstract
Introduction Immunological protection against human immunodeficiency virus-1 (HIV-1) infection is likely to require both humoral and cell-mediated immune responses, the latter involving cytotoxic CD8 T-cells. Characterisation of CD8 T-cell mediated direct anti-viral activity would provide understanding of potential correlates of immune protection and identification of critical epitopes associated with HIV-1 control. Methods The present report describes a functional viral inhibition assay (VIA) to assess CD8 T-cell-mediated inhibition of replication of a large and diverse panel of 45 HIV-1 infectious molecular clones (IMC) engineered with a Renilla reniformis luciferase reporter gene (LucR), referred to as IMC-LucR. HIV-1 IMC replication in CD4 T-cells and CD8 T-cell mediated inhibition was characterised in both ART naive subjects living with HIV-1 covering a broad human leukocyte antigen (HLA) distribution and compared with uninfected subjects. Results & discussion CD4 and CD8 T-cell lines were established from subjects vaccinated with a candidate HIV-1 vaccine and provided standard positive controls for both assay quality control and facilitating training and technology transfer. The assay was successfully established across 3 clinical research centres in Kenya, Uganda and the United Kingdom and shown to be reproducible. This IMC-LucR VIA enables characterisation of functional CD8 T-cell responses providing a tool for rational T-cell immunogen design of HIV-1 vaccine candidates and evaluation of vaccine-induced T-cell responses in HIV-1 clinical trials.
Collapse
Affiliation(s)
- Natalia Fernandez
- IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom,*Correspondence: Natalia Fernandez, ; Peter Hayes,
| | - Peter Hayes
- IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom,*Correspondence: Natalia Fernandez, ; Peter Hayes,
| | - Julia Makinde
- IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom
| | - Jonathan Hare
- IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom,IAVI, New York, NY, United States
| | - Deborah King
- IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom
| | - Rui Xu
- Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States
| | - Ola Rehawi
- University of Alabama at Birmingham, Birmingham, AL, United States
| | | | - Laban Kato
- Uganda Virus Research Institute, Entebbe, Uganda,Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Susan Mugaba
- Uganda Virus Research Institute, Entebbe, Uganda,Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Jennifer Serwanga
- Uganda Virus Research Institute, Entebbe, Uganda,Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - James Chemweno
- Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme, Kilifi, Kenya
| | - Eunice Nduati
- Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme, Kilifi, Kenya
| | - Matt A. Price
- IAVI, New York, NY, United States,Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, United States
| | - Faith Osier
- IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom
| | | | - Ling Yue
- Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States
| | - Eric Hunter
- Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States
| | - Jill Gilmour
- Department of Infectious Diseases, Imperial College, London, United Kingdom
| | | |
Collapse
|
11
|
Sidiqi B, Parakrama R, Demyan L, Eckstein J, Nosrati J, Chitti B, Pasha S, Pinto D, Zavadsky T, Zou X, Patruni S, Kapusta A, Weiss M, King D, Herman J, Ghaly M. Stereotactic Body Radiation Therapy (SBRT) in a Standardized Neoadjuvant Therapy Pathway for Pancreatic Cancer across a Geographically Large and Diverse Healthcare System. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
12
|
Allevato M, Oliana O, King D, Mora F, Blade M, Hauzman E, Pandian Z, Vlismas A, Trew G. Ongoing clinical pregnancy after the transfer of a one pronuclei (1PN) euploid embryo tested for bi-parental DNA inheritance with the Parent of Origin Test (PoOt). Reprod Biomed Online 2022. [DOI: 10.1016/j.rbmo.2022.08.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Nocente M, Kiptily V, Tardocchi M, Bonofiglo PJ, Craciunescu T, Molin AD, De La Luna E, Eriksson J, Garcia J, Ghani Z, Gorini G, Hägg L, Kazakov Y, Lerche E, Maggi CF, Mantica P, Marcer G, Maslov M, Putignano O, Rigamonti D, Salewski M, Sharapov S, Siren P, Stancar Z, Zohar A, Beaumont P, Crombe K, Ericsson G, Garcia-Munoz M, Keeling D, King D, Kirov K, Nave MFF, Ongena J, Patel A, Perez von Thun C. Fusion product measurements by nuclear diagnostics in the Joint European Torus deuterium-tritium 2 campaign (invited). Rev Sci Instrum 2022; 93:093520. [PMID: 36182523 DOI: 10.1063/5.0101767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 08/20/2022] [Indexed: 06/16/2023]
Abstract
A new deuterium-tritium experimental, DTE2, campaign has been conducted at the Joint European Torus (JET) between August 2021 and late December 2021. Motivated by significant enhancements in the past decade at JET, such as the ITER-like wall and enhanced auxiliary heating power, the campaign achieved a new fusion energy world record and performed a broad range of fundamental experiments to inform ITER physics scenarios and operations. New capabilities in the area of fusion product measurements by nuclear diagnostics were available as a result of a decade long enhancement program. These have been tested for the first time in DTE2 and a concise overview is provided here. Confined alpha particle measurements by gamma-ray spectroscopy were successfully demonstrated, albeit with limitations at neutron rates higher than some 1017 n/s. High resolution neutron spectroscopy measurements with the magnetic proton recoil instrument were complemented by novel data from a set of synthetic diamond detectors, which enabled studies of the supra-thermal contributions to the neutron emission. In the area of escaping fast ion diagnostics, a lost fast ion detector and a set of Faraday cups made it possible to determine information on the velocity space and poloidal distribution of the lost alpha particles for the first time. This extensive set of data provides unique information for fundamental physics studies and validation of the numerical models, which are key to inform the physics and scenarios of ITER.
Collapse
Affiliation(s)
- M Nocente
- Department of Physics, University of Milano-Bicocca, Milan 20126, Italy
| | - V Kiptily
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - M Tardocchi
- Institute for Plasma Science and Technology, National Research Council, Milan 20125, Italy
| | - P J Bonofiglo
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540, USA
| | - T Craciunescu
- Institute of Atomic Physics, Magurele-Bucharest 077125, Romania
| | - A Dal Molin
- Institute for Plasma Science and Technology, National Research Council, Milan 20125, Italy
| | - E De La Luna
- Laboratorio Nacional de Fusión, CIEMAT, Madrid 28040, Spain
| | - J Eriksson
- Department of Physics and Astronomy, Uppsala University, Uppsala SE-75120, Sweden
| | - J Garcia
- CEA, IRFM, Saint Paul lez Durance 13115, France
| | - Z Ghani
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - G Gorini
- Department of Physics, University of Milano-Bicocca, Milan 20126, Italy
| | - L Hägg
- Department of Physics and Astronomy, Uppsala University, Uppsala SE-75120, Sweden
| | - Y Kazakov
- Laboratory for Plasma Physics, LPP ERM/KMS, Brussels 1000, Belgium
| | - E Lerche
- Laboratory for Plasma Physics, LPP ERM/KMS, Brussels 1000, Belgium
| | - C F Maggi
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - P Mantica
- Institute for Plasma Science and Technology, National Research Council, Milan 20125, Italy
| | - G Marcer
- Department of Physics, University of Milano-Bicocca, Milan 20126, Italy
| | - M Maslov
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - O Putignano
- Department of Physics, University of Milano-Bicocca, Milan 20126, Italy
| | - D Rigamonti
- Institute for Plasma Science and Technology, National Research Council, Milan 20125, Italy
| | - M Salewski
- Department of Physics, Technical University of Denmark, Kgs. Lyngby 2800, Denmark
| | - S Sharapov
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - P Siren
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - Z Stancar
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - A Zohar
- Jožef Stefan Institute, Ljubljana 1000, Slovenia
| | - P Beaumont
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - K Crombe
- Laboratory for Plasma Physics, LPP ERM/KMS, Brussels 1000, Belgium
| | - G Ericsson
- Department of Physics and Astronomy, Uppsala University, Uppsala SE-75120, Sweden
| | - M Garcia-Munoz
- Department of Atomic, Molecular and Nuclear Physics, University of Seville, Seville 41012, Spain
| | - D Keeling
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - D King
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - K Kirov
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - M F F Nave
- Instituto de Plasmas e Fusao Nuclear, IST, Universidade de Lisboa, Lisboa 1049-001, Portugal
| | - J Ongena
- Laboratory for Plasma Physics, LPP ERM/KMS, Brussels 1000, Belgium
| | - A Patel
- United Kingdom Atomic Energy Authority, Culham Centre for Fusion Energy, Culham Science Centre, Abingdon OX14 3DB, United Kingdom
| | - C Perez von Thun
- Institute of Plasma Physics and Laser Microfusion, Warsaw 01-497, Poland
| |
Collapse
|
14
|
Kibirige CN, Manak M, King D, Abel B, Hack H, Wooding D, Liu Y, Fernandez N, Dalel J, Kaye S, Imami N, Jagodzinski L, Gilmour J. Author Correction: Development of a sensitive, quantitative assay with broad subtype specificity for detection of total HIV-1 nucleic acids in plasma and PBMC. Sci Rep 2022; 12:11792. [PMID: 35821052 PMCID: PMC9276778 DOI: 10.1038/s41598-022-16308-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- C N Kibirige
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK.
| | - M Manak
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.,U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA.,Turesol Consulting, 314 S. Henderson Road, King of Prussia, PA, 19406, USA
| | - D King
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - B Abel
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - H Hack
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.,U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA.,Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - D Wooding
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - Y Liu
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.,U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA.,Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - N Fernandez
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - J Dalel
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - Steve Kaye
- Molecular Diagnostics Unit, Imperial College London, Jeferiss Trust Laboratory, St. Mary's Campus, Norfolk Place, London, W2 1PG, UK
| | - N Imami
- Centre for Immunology and Vaccinology, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - L Jagodzinski
- U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA.,Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - J Gilmour
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| |
Collapse
|
15
|
Atkins R, Dugan MA, Jakubowski T, Perron T, King D, McSweeney M, Ivanof V, Johnson S. Service learning: Nursing students' civic engagement with diverse populations of children with special needs. J Pediatr Nurs 2022; 65:1-9. [PMID: 35367854 DOI: 10.1016/j.pedn.2022.02.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2021] [Revised: 02/17/2022] [Accepted: 02/19/2022] [Indexed: 12/17/2022]
Abstract
PURPOSE There is limited knowledge of nursing students' perspectives about engagement with special needs populations. The purpose of this study was to identify the advantages/benefits and disadvantages/challenges of nursing students' engagement experience with children with special mental and physical disabilities. Recommendations to enhance student engagement experiences were also provided. METHODS A descriptive, qualitative design was employed. Undergraduate nursing students (N = 28) responded to open-ended questions about their civic engagement experiences at a community-based, respite care program for children with special needs. Student accounts underwent directed content analysis, with coding, category and theme development according to the Theory of Planned Behavior. The Atlas.Ti computer program was used to manage the data. RESULTS Advantages/Benefits: Filling cognitive and experiential learning gaps, rewarding connections/relationships, positive emotions, perceptions and interactions, and fun and stress relief. Disadvantage/challenges: Managing negative/uncomfortable emotions and uncertainty, witnessing and managing disruptive behaviors, negative perceptions of program operations/expectations. CONCLUSIONS Students experienced cognitive, emotional, interpersonal and educational advantages and/or disadvantages while engaging with this defined population. PRACTICE IMPLICATIONS To enhance engagement faculty can provide education and anticipatory guidance, detail responsibilities and expectations, and/or utilize simulation for student preparation. Nurses and researchers can utilize community based participatory methods to guide discussions with community-based organizations to collaboratively develop strategies to institute, evaluate and enhance student engagement during service learning experiences with children who have special needs.
Collapse
Affiliation(s)
- Rahshida Atkins
- School of Nursing and Health Sciences, The College of New Jersey, 2000 Pennington Road, Ewing, NJ 08628, United States of America.
| | - Mary Ann Dugan
- School of Nursing and Health Sciences, The College of New Jersey, 2000 Pennington Road, Ewing, NJ 08628, United States of America.
| | - Tami Jakubowski
- School of Nursing and Health Sciences, The College of New Jersey, 2000 Pennington Road, Ewing, NJ 08628, United States of America.
| | - Tracy Perron
- School of Nursing and Health Sciences, The College of New Jersey, 2000 Pennington Road, Ewing, NJ 08628, United States of America.
| | - Deborah King
- School of Nursing and Health Sciences, The College of New Jersey, 2000 Pennington Road, Ewing, NJ 08628, United States of America; Villanova University M. Louise Fitzpatrick College of Nursing 800 Lancaster Ave. Villanova, PA 19085, United States of America.
| | - Madeline McSweeney
- School of Nursing and Health Sciences, The College of New Jersey, 2000 Pennington Road, Ewing, NJ 08628, United States of America.
| | - Vyacheslav Ivanof
- School of Nursing and Health Sciences, The College of New Jersey, 2000 Pennington Road, Ewing, NJ 08628, United States of America.
| | - Shanda Johnson
- New Jersey City University (NJCU), 2039 Kennedy Blvd, Jersey City, New Jersey 07305, United States of America.
| |
Collapse
|
16
|
Parakrama R, Sidiqi B, Demyan L, Pasha S, Pinto D, Zavadsky T, Zou X, Patruni S, Kapusta A, Standring O, Weiss M, Herman J, King D. P-10 Standardization of a neoadjuvant therapy (NAT) pathway for pancreatic cancer across a geographically large and diverse healthcare system improves patient care and successful completion of NAT. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
17
|
Abrams D, Albataineh H, Aljawrneh BS, Alsalmi S, Androic D, Aniol K, Armstrong W, Arrington J, Atac H, Averett T, Gayoso CA, Bai X, Bane J, Barcus S, Beck A, Bellini V, Bhatt H, Bhetuwal D, Biswas D, Blyth D, Boeglin W, Bulumulla D, Butler J, Camsonne A, Carmignotto M, Castellanos J, Chen JP, Cohen EO, Covrig S, Craycraft K, Cruz-Torres R, Dongwi B, Duran B, Dutta D, Fuchey E, Gal C, Gautam TN, Gilad S, Gnanvo K, Gogami T, Gomez J, Gu C, Habarakada A, Hague T, Hansen JO, Hattawy M, Hauenstein F, Higinbotham DW, Holt RJ, Hughes EW, Hyde C, Ibrahim H, Jian S, Joosten S, Karki A, Karki B, Katramatou AT, Keith C, Keppel C, Khachatryan M, Khachatryan V, Khanal A, Kievsky A, King D, King PM, Korover I, Kulagin SA, Kumar KS, Kutz T, Lashley-Colthirst N, Li S, Li W, Liu H, Liuti S, Liyanage N, Markowitz P, McClellan RE, Meekins D, Beck SMT, Meziani ZE, Michaels R, Mihovilovic M, Nelyubin V, Nguyen D, Nycz M, Obrecht R, Olson M, Owen VF, Pace E, Pandey B, Pandey V, Paolone M, Papadopoulou A, Park S, Paul S, Petratos GG, Petti R, Piasetzky E, Pomatsalyuk R, Premathilake S, Puckett AJR, Punjabi V, Ransome RD, Rashad MNH, Reimer PE, Riordan S, Roche J, Salmè G, Santiesteban N, Sawatzky B, Scopetta S, Schmidt A, Schmookler B, Segal J, Segarra EP, Shahinyan A, Širca S, Sparveris N, Su T, Suleiman R, Szumila-Vance H, Tadepalli AS, Tang L, Tireman W, Tortorici F, Urciuoli GM, Wojtsekhowski B, Wood S, Ye ZH, Ye ZY, Zhang J. Measurement of the Nucleon F_{2}^{n}/F_{2}^{p} Structure Function Ratio by the Jefferson Lab MARATHON Tritium/Helium-3 Deep Inelastic Scattering Experiment. Phys Rev Lett 2022; 128:132003. [PMID: 35426713 DOI: 10.1103/physrevlett.128.132003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Revised: 01/23/2022] [Accepted: 02/09/2022] [Indexed: 06/14/2023]
Abstract
The ratio of the nucleon F_{2} structure functions, F_{2}^{n}/F_{2}^{p}, is determined by the MARATHON experiment from measurements of deep inelastic scattering of electrons from ^{3}H and ^{3}He nuclei. The experiment was performed in the Hall A Facility of Jefferson Lab using two high-resolution spectrometers for electron detection, and a cryogenic target system which included a low-activity tritium cell. The data analysis used a novel technique exploiting the mirror symmetry of the two nuclei, which essentially eliminates many theoretical uncertainties in the extraction of the ratio. The results, which cover the Bjorken scaling variable range 0.19<x<0.83, represent a significant improvement compared to previous SLAC and Jefferson Lab measurements for the ratio. They are compared to recent theoretical calculations and empirical determinations of the F_{2}^{n}/F_{2}^{p} ratio.
Collapse
Affiliation(s)
- D Abrams
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Albataineh
- Texas A & M University, Kingsville, Texas 78363, USA
| | - B S Aljawrneh
- North Carolina A & T State University, Greensboro, North Carolina 27411, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
- King Saud University, Riyadh 11451, Kingdom of Saudi Arabia
| | - D Androic
- University of Zagreb, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, California 90032, USA
| | - W Armstrong
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Arrington
- Argonne National Laboratory, Lemont, Illinois 60439, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- William & Mary, Williamsburg, Virginia 23187, USA
| | | | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- William & Mary, Williamsburg, Virginia 23187, USA
| | - A Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | - H Bhatt
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - D Bhetuwal
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - D Blyth
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - W Boeglin
- Florida International University, Miami, Florida 33199, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J Butler
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - A Camsonne
- Jefferson Lab, Newport News, Virginia 23606, USA
| | | | - J Castellanos
- Florida International University, Miami, Florida 33199, USA
| | - J-P Chen
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - E O Cohen
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, Israel
| | - S Covrig
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - K Craycraft
- William & Mary, Williamsburg, Virginia 23187, USA
| | - R Cruz-Torres
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Dongwi
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Dutta
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T N Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - S Gilad
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Gogami
- Tohoku University, Sendai 980-8576, Japan
| | - J Gomez
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Habarakada
- Hampton University, Hampton, Virginia 23669, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - J-O Hansen
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Hattawy
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | | | - R J Holt
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - E W Hughes
- Columbia University, New York, New York 10027, USA
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo, Giza 12613 Egypt
| | - S Jian
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Joosten
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A Karki
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | | | - C Keith
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - C Keppel
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Khachatryan
- Stony Brook, State University of New York, New York 11794, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - A Kievsky
- Istituto Nazionale di Fisica Nucleare, Sezione di Pisa, 56127 Pisa, Italy
| | - D King
- Syracuse University, Syracuse, New York 13244, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - I Korover
- Nuclear Research Center-Negev, Beer-Sheva 84190, Israel
| | - S A Kulagin
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - K S Kumar
- Stony Brook, State University of New York, New York 11794, USA
| | - T Kutz
- Stony Brook, State University of New York, New York 11794, USA
| | | | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W Li
- University of Regina, Regina, Saskatchewan S4S 0A2, Canada
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - S Liuti
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Liyanage
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | | | - D Meekins
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - S Mey-Tal Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Z-E Meziani
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Michaels
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Mihovilovic
- Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana 1000, Slovenia
- Jožef Stefan Institute, Ljubljana, Slovenia
- Institut für Kernphysik, Johannes Gutenberg-Universität, Mainz 55122, Germany
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - R Obrecht
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Olson
- Saint Norbert College, De Pere, Wisconsin 54115, USA
| | - V F Owen
- William & Mary, Williamsburg, Virginia 23187, USA
| | - E Pace
- University of Rome Tor Vergata and INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - V Pandey
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - M Paolone
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A Papadopoulou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - S Paul
- William & Mary, Williamsburg, Virginia 23187, USA
| | | | - R Petti
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - E Piasetzky
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, Israel
| | - R Pomatsalyuk
- Institute of Physics and Technology, 61108 Kharkov, Ukraine
| | - S Premathilake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R D Ransome
- Rutgers, The State University of New Jersey, Piscataway, New Jersey 08855, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - P E Reimer
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - S Riordan
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - G Salmè
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma, 00185 Rome, Italy
| | - N Santiesteban
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - B Sawatzky
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - S Scopetta
- University of Perugia and INFN, Sezione di Perugia, 06123 Perugia, Italy
| | - A Schmidt
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J Segal
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - E P Segarra
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Shahinyan
- Yerevan Physics Institute, Yerevan 375036, Armenia
| | - S Širca
- Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana 1000, Slovenia
- Jožef Stefan Institute, Ljubljana, Slovenia
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
- Shandong Institute of Advanced Technology, Jinan, Shandong 250100, China
| | - R Suleiman
- Jefferson Lab, Newport News, Virginia 23606, USA
| | | | - A S Tadepalli
- Rutgers, The State University of New Jersey, Piscataway, New Jersey 08855, USA
| | - L Tang
- Hampton University, Hampton, Virginia 23669, USA
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - W Tireman
- Northern Michigan University, Marquette, Michigan 49855, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma, 00185 Rome, Italy
| | | | - S Wood
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - Z H Ye
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - Z Y Ye
- University of Illinois-Chicago, Chicago, Illinois 60607, USA
| | - J Zhang
- Stony Brook, State University of New York, New York 11794, USA
| |
Collapse
|
18
|
Hecimovich M, King D, Murphy M, Koyama K. An investigation into the measurement properties of the King-Devick Eye Tracking system. Journal of Concussion 2022. [DOI: 10.1177/20597002221082865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Objectives Eye tracking has been gaining increasing attention as a possible assessment and monitoring tool for concussion. The King-Devick test (K-DT) was expanded to include an infrared video-oculography-based eye tracker (K-D ET). Therefore, the aim was to provide evidence on the reliability of the K-D ET system under an exercise condition. Methods Participants (N = 61; 26 male, 35 female; age range 19-25) were allocated to an exercise or sedentary group. Both groups completed a baseline K-D ET measurement and then either two 10-min exercise or sedentary interventions with repeated K-D ET measurements between interventions. Results The test-retest reliability of the K-D ET ranged from good to excellent for the different variables measured. The mean ± SD of the differences for the total number of saccades was 1.04 ± 4.01 and there was an observable difference (p = 0.005) in the trial number. There were no observable differences for the intervention (p = 0.768), gender (p = 0.121) and trial (p = 0.777) for average saccade’s velocity. The mean ± SD of the difference of the total fixations before and after intervention across both trials was 1.04 ± 3.63 and there was an observable difference in the trial number (p = 0.025). The mean ± SD of the differences for the Inter-Saccadic Interval and the fixation polyarea before and after intervention across both trials were 1.86 ± 22.99 msec and 0.51 ± 59.11 mm2 and no observable differences for the intervention, gender and trial. Conclusion The results provide evidence on the reliability of the K-D ET, and the eye-tracking components and demonstrate the relationship between completion time and other variables of the K-D ET system. This is vital as the use of the K-DT may be increasing and the combination of the K-DT and eye tracking as one single package highlights the need to specifically measure the reliability of this combined unit.
Collapse
Affiliation(s)
- M. Hecimovich
- Division of Athletic Training, University of Northern Iowa, Cedar Falls, Iowa, USA
| | - D. King
- Sports Performance Research Institute New Zealand (SPRINZ) at AUT Millennium, Faculty of Health and Environmental Science, Auckland University of Technology, Auckland, New Zealand
- Traumatic Brain injury Network (TBIN), Auckland University of Technology, Auckland, New Zealand
- Department of Science and Technology, University of New England, Sydney, Australia
| | - M. Murphy
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
- SportsMed Subiaco, St John of God Health Care, Subiaco, Western Australia, Australia
| | - K. Koyama
- Department of Rehabilitation Medicine, Gunma University Graduate School of Medicine
| |
Collapse
|
19
|
Kibirige CN, Manak M, King D, Abel B, Hack H, Wooding D, Liu Y, Fernandez N, Dalel J, Kaye S, Imami N, Jagodzinski L, Gilmour J. Author Correction: Development of a sensitive, quantitative assay with broad subtype specificity for detection of total HIV-1 nucleic acids in plasma and PBMC. Sci Rep 2022; 12:1980. [PMID: 35105930 PMCID: PMC8807713 DOI: 10.1038/s41598-022-06286-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- C. N. Kibirige
- grid.428062.a0000 0004 0497 2835IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH UK
| | - M. Manak
- grid.201075.10000 0004 0614 9826Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD USA ,grid.507680.c0000 0001 2230 3166U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD 20910 USA ,Present Address: Turesol Consulting, 314 S. Henderson Road, King of Prussia, PA 19406 USA
| | - D. King
- grid.428062.a0000 0004 0497 2835IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH UK
| | - B. Abel
- grid.428062.a0000 0004 0497 2835IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH UK
| | - H. Hack
- grid.201075.10000 0004 0614 9826Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD USA ,grid.507680.c0000 0001 2230 3166U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD 20910 USA ,grid.507680.c0000 0001 2230 3166Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910 USA
| | - D. Wooding
- grid.428062.a0000 0004 0497 2835IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH UK
| | - Y. Liu
- grid.201075.10000 0004 0614 9826Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD USA ,grid.507680.c0000 0001 2230 3166U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD 20910 USA ,grid.507680.c0000 0001 2230 3166Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910 USA
| | - N. Fernandez
- grid.428062.a0000 0004 0497 2835IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH UK
| | - J. Dalel
- grid.428062.a0000 0004 0497 2835IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH UK
| | - Steve Kaye
- grid.7445.20000 0001 2113 8111Molecular Diagnostics Unit, Imperial College London, Jefferiss Trust Laboratory, St. Mary’s Campus, Norfolk Place, London, W2 1PG UK
| | - N. Imami
- grid.428062.a0000 0004 0497 2835Centre for Immunology and Vaccinology, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH UK
| | - L. Jagodzinski
- grid.507680.c0000 0001 2230 3166U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD 20910 USA ,grid.507680.c0000 0001 2230 3166Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910 USA
| | - J. Gilmour
- grid.428062.a0000 0004 0497 2835IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH UK
| |
Collapse
|
20
|
Kibirige CN, Manak M, King D, Abel B, Hack H, Wooding D, Liu Y, Fernandez N, Dalel J, Kaye S, Imami N, Jagodzinski L, Gilmour J. Development of a sensitive, quantitative assay with broad subtype specificity for detection of total HIV-1 nucleic acids in plasma and PBMC. Sci Rep 2022; 12:1550. [PMID: 35091568 PMCID: PMC8799642 DOI: 10.1038/s41598-021-03016-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Accepted: 10/28/2021] [Indexed: 11/09/2022] Open
Abstract
An LTR-based quantitative PCR (qPCR) assay was modified and optimized for the quantification of total HIV-1 nucleic acids in plasma and PBMC. TaqMan qPCR primers and probes were designed against the NCBI/LANL HIV-1 compendium database by analyzing sequences used in assays for sensitive cross-clade detection of HIV-1 as reported in the literature and elucidating regions of improved cross-subtype specificity. Inosine and mixed nucleotide bases were included at polymorphic sites. Real-time RT-qPCR and qPCR were performed on plasma viral RNA and cellular lysates. A step-up amplification approach to allow binding of primers across polymorphic regions showed improved sensitivity compared to universal cycling. Unlike a lead competing laboratory-developed assay, all major HIV-1 subtypes, and a wide range of recombinants from a 127-member diversity panel were detected and accurately quantified in spiked plasmas. Semi-nested PCR increased detection sensitivity even further. The assay was able to detect down to 88 copies/mL of HIV-1 in plasma with 95% efficiency or the equivalent of a single infected cell. The PCR assay will be valuable in studies that monitor very low viral levels including residual or break through HIV-1 in patients receiving antiretroviral therapy, in HIV-1 cure, and in other research studies.
Collapse
Affiliation(s)
- C N Kibirige
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK.
| | - M Manak
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
- U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD, 20910, USA
- Turesol Consulting, 314 S. Henderson Road, King of Prussia, PA, 19406, USA
| | - D King
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - B Abel
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - H Hack
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
- U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD, 20910, USA
- Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - D Wooding
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - Y Liu
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
- U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD, 20910, USA
- Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - N Fernandez
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - J Dalel
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - Steve Kaye
- Molecular Diagnostics Unit, Imperial College London, Jefferiss Trust Laboratory, St. Mary's Campus, Norfolk Place, London, W2 1PG, UK
| | - N Imami
- Centre for Immunology and Vaccinology, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| | - L Jagodzinski
- U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD, 20910, USA
- Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - J Gilmour
- IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
| |
Collapse
|
21
|
Bouquet J, Auberger N, Ashmus R, King D, Bordes A, Fontelle N, Nakagawa S, Madden Z, Proceviat C, Kato A, Désiré J, Vocadlo DJ, Blériot Y. Structural variation of the 3-acetamido-4,5,6-trihydroxyazepane iminosugar through epimerization and C-alkylation leads to low micromolar HexAB and NagZ inhibitors. Org Biomol Chem 2021; 20:619-629. [PMID: 34940771 DOI: 10.1039/d1ob02280f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We report the synthesis of seven-membered iminosugars derived from a 3S-acetamido-4R,5R,6S-trihydroxyazepane scaffold and their evaluation as inhibitors of functionally related exo-N-acetylhexosaminidases including human O-GlcNAcase (OGA), human lysosomal β-hexosaminidase (HexAB), and Escherichia coli NagZ. Capitalizing on the flexibility of azepanes and the active site tolerances of hexosaminidases, we explore the effects of epimerization of stereocenters at C-3, C-5 and C-6 and C-alkylation at the C-2 or C-7 positions. Accordingly, epimerization at C-6 (L-ido) and at C-5 (D-galacto) led to selective HexAB inhibitors whereas introduction of a propyl group at C-7 on the C-3 epimer furnished a potent NagZ inhibitor.
Collapse
Affiliation(s)
- J Bouquet
- Université de Poitiers, IC2MP, UMR CNRS 7285, OrgaSynth Team, Glyco group, 4 rue Michel Brunet, 86073 Poitiers cedex 09, France.
| | - N Auberger
- Université de Poitiers, IC2MP, UMR CNRS 7285, OrgaSynth Team, Glyco group, 4 rue Michel Brunet, 86073 Poitiers cedex 09, France.
| | - R Ashmus
- Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia, V5S 1P6, Canada.
| | - D King
- Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia, V5S 1P6, Canada.
| | - A Bordes
- Université de Poitiers, IC2MP, UMR CNRS 7285, OrgaSynth Team, Glyco group, 4 rue Michel Brunet, 86073 Poitiers cedex 09, France.
| | - N Fontelle
- Université de Poitiers, IC2MP, UMR CNRS 7285, OrgaSynth Team, Glyco group, 4 rue Michel Brunet, 86073 Poitiers cedex 09, France.
| | - S Nakagawa
- Department of Hospital Pharmacy, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
| | - Z Madden
- Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia, V5S 1P6, Canada.
| | - C Proceviat
- Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia, V5S 1P6, Canada.
| | - A Kato
- Department of Hospital Pharmacy, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
| | - J Désiré
- Université de Poitiers, IC2MP, UMR CNRS 7285, OrgaSynth Team, Glyco group, 4 rue Michel Brunet, 86073 Poitiers cedex 09, France.
| | - D J Vocadlo
- Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia, V5S 1P6, Canada.
| | - Y Blériot
- Université de Poitiers, IC2MP, UMR CNRS 7285, OrgaSynth Team, Glyco group, 4 rue Michel Brunet, 86073 Poitiers cedex 09, France.
| |
Collapse
|
22
|
Allen SK, Brown V, White D, King D, Hunt J, Wainwright J, Emery A, Hodge E, Kehinde A, Prabhu P, Rockall TA, Preston SR, Sultan J. ASO Visual Abstract: Multi-modal Prehabilitation During Neoadjuvant Therapy Before Esophagogastric Cancer Resection: Effect on Cardiopulmonary Exercise Test Performance, Muscle Mass, and Quality of Life-A Pilot Randomized Clinical Trial. Ann Surg Oncol 2021. [PMID: 34797478 DOI: 10.1245/s10434-021-11062-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- S K Allen
- Department of General Surgery, The Royal Surrey NHS Foundation Trust Hospital, Guildford, UK.,Minimal Access Therapy Training Unit (MATTU), Guildford, UK
| | - V Brown
- Department of General Surgery, The Royal Surrey NHS Foundation Trust Hospital, Guildford, UK.,Minimal Access Therapy Training Unit (MATTU), Guildford, UK
| | - D White
- Department of General Surgery, The Royal Surrey NHS Foundation Trust Hospital, Guildford, UK.,Minimal Access Therapy Training Unit (MATTU), Guildford, UK
| | - D King
- Faculty of Health and Medical Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, UK
| | - J Hunt
- Faculty of Health and Medical Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, UK
| | - J Wainwright
- Faculty of Health and Medical Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, UK
| | - A Emery
- Faculty of Health and Medical Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, UK
| | - E Hodge
- The Fountain Centre, St Luke's Cancer Centre, Guildford, UK
| | - A Kehinde
- The Fountain Centre, St Luke's Cancer Centre, Guildford, UK
| | - P Prabhu
- Department of Anaesthetics, The Royal Surrey NHS Foundation Trust Hospital, Guildford, UK
| | - T A Rockall
- Department of General Surgery, The Royal Surrey NHS Foundation Trust Hospital, Guildford, UK.,Minimal Access Therapy Training Unit (MATTU), Guildford, UK
| | - S R Preston
- Department of General Surgery, The Royal Surrey NHS Foundation Trust Hospital, Guildford, UK
| | - Javed Sultan
- Department of General Surgery, The Royal Surrey NHS Foundation Trust Hospital, Guildford, UK.
| |
Collapse
|
23
|
Grossman C, Barr C, King D, McKenney C, Koenick S, Chang R. Management and cleanup of legacy radium-contaminated sites in the United States. J Radiol Prot 2021; 41:S230-S253. [PMID: 34426564 DOI: 10.1088/1361-6498/abe98a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Accepted: 02/24/2021] [Indexed: 06/13/2023]
Abstract
The hazards associated with radium-containing materials were largely unknown when they were first introduced into household and other products over a century ago. Radium was also originally thought to have beneficial health properties, leading to confusion amongst the public about the safety of radium in household products and food items. When the adverse health effects associated with radium were discovered and became well known, radium products became unpopular and were prohibited in some countries. In the United States, after the hazards associated with radium became known, radium was first regulated by individual states in the late 1920s and early 1930s. Later, the US Nuclear Regulatory Commission (NRC) was given a role in the regulation of discrete sources of radium with the passage of the Energy Policy Act of 2005. After passage of the Act, the NRC began to systematically identify sites around the country where radium was used and reached out to site owners to determine whether existing radium contamination could pose a risk to public health and safety and the environment. The NRC devised a graded approach in response to its new regulatory responsibilities to address potential public health and safety issues at legacy radium sites. By September 2019, the NRC had dispositioned all the sites that were identified as having potential contamination from historical radium within its regulatory purview in non-Agreement States. The staff worked with site owners and federal, state and local officials, as needed, to properly disposition the sites to ensure that each site either meets the applicable criteria for unrestricted use or has controls in place to limit access during remediation so that no site poses an unacceptable risk to public health and safety and the environment.
Collapse
Affiliation(s)
- C Grossman
- United States Nuclear Regulatory Commission, Washington, DC 20555
| | - C Barr
- United States Nuclear Regulatory Commission, Washington, DC 20555
| | - D King
- Oak Ridge Associated Universities, Oak Ridge, TN 37830
| | - C McKenney
- United States Nuclear Regulatory Commission, Washington, DC 20555
| | - S Koenick
- United States Nuclear Regulatory Commission, Washington, DC 20555
| | - R Chang
- United States Nuclear Regulatory Commission, Washington, DC 20555
| |
Collapse
|
24
|
Levine MM, Abdullah S, Arabi YM, Darko DM, Durbin AP, Estrada V, Jamrozik E, Kremsner PG, Lagos R, Pitisuttithum P, Plotkin SA, Sauerwein R, Shi SL, Sommerfelt H, Subbarao K, Treanor JJ, Vrati S, King D, Balasingam S, Weller C, Aguilar AO, Cassetti MC, Krause PR, Restrepo AMH. Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers. Clin Infect Dis 2021; 72:2035-2041. [PMID: 32857836 PMCID: PMC7499532 DOI: 10.1093/cid/ciaa1290] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Indexed: 12/16/2022] Open
Abstract
WHO convened an Advisory Group (AG) to consider the feasibility, potential value, and limitations of establishing a closely-monitored challenge model of experimental severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) in healthy adult volunteers. The AG included experts in design, establishment, and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (the potential of SARS-CoV-2 to cause severe/fatal illness, its high transmissibility, and lack of a "rescue treatment" to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.
Collapse
Affiliation(s)
- Myron M Levine
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | | | - Yaseen M Arabi
- College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia
| | | | - Anna P Durbin
- Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
| | - Vicente Estrada
- Medical School, Complutense University, Hospital Clínico San Carlos, Madrid, Spain
| | | | - Peter G Kremsner
- Institut für Tropenmedizin, Universitätsklinikum Tübingen, Germany.,Centre de Recherches Médicales de Lambaréné, Gabon
| | - Rosanna Lagos
- Centro para Vacunas en Desarrollo (CVD-Chile), Santiago, Chile
| | - Punnee Pitisuttithum
- Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
| | - Stanley A Plotkin
- Department of Pediatrics, University of Pennsylvania, Doylestown, Pennsylvania, USA
| | - Robert Sauerwein
- Medical Parasitology Department, Radboud University, Nijmegen, The Netherlands
| | - Sheng-Li Shi
- Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Wuhan, China
| | - Halvor Sommerfelt
- Centre for Intervention Science in Maternal and Child Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, and Norwegian Institute of Public Health, Oslo, Norway
| | - Kanta Subbarao
- WHO Collaborating Centre for Reference and Research on Influenza and Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute, Melbourne, Australia
| | - John J Treanor
- Infectious Diseases Division, University of Rochester Medical Center, Rochester, New York, USA
| | - Sudhanshu Vrati
- Regional Centre for Biotechnology, Haryana (NCR Delhi), India
| | - Deborah King
- Vaccines Priority Area, Wellcome Trust, London, United Kingdom
| | | | - Charlie Weller
- Vaccines Programme, Wellcome Trust, London, United Kingdom
| | - Anastazia Older Aguilar
- Global Health Discovery & Translational Sciences, Bill & Melinda Gates Foundation, Seattle, Washington, USA
| | - M Cristina Cassetti
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
| | - Philip R Krause
- Office of Vaccines Research and Review, CEBR, FDA, Silver Spring, Maryland, USA.,Chair, WHO R&D Blueprint COVID-19 Vaccines Working Group
| | - Ana Maria Henao Restrepo
- Office of the Executive Director (WHE), WHO Health Emergencies Programme, World Health Organization, Geneva, Switzerland
| |
Collapse
|
25
|
Makinde J, Nduati EW, Freni-Sterrantino A, Streatfield C, Kibirige C, Dalel J, Black SL, Hayes P, Macharia G, Hare J, McGowan E, Abel B, King D, Joseph S, Hunter E, Sanders EJ, Price M, Gilmour J. A Novel Sample Selection Approach to Aid the Identification of Factors That Correlate With the Control of HIV-1 Infection. Front Immunol 2021; 12:634832. [PMID: 33777023 PMCID: PMC7991997 DOI: 10.3389/fimmu.2021.634832] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Accepted: 02/08/2021] [Indexed: 12/11/2022] Open
Abstract
Individuals infected with HIV display varying rates of viral control and disease progression, with a small percentage of individuals being able to spontaneously control infection in the absence of treatment. In attempting to define the correlates associated with natural protection against HIV, extreme heterogeneity in the datasets generated from systems methodologies can be further complicated by the inherent variability encountered at the population, individual, cellular and molecular levels. Furthermore, such studies have been limited by the paucity of well-characterised samples and linked epidemiological data, including duration of infection and clinical outcomes. To address this, we selected 10 volunteers who rapidly and persistently controlled HIV, and 10 volunteers each, from two control groups who failed to control (based on set point viral loads) from an acute and early HIV prospective cohort from East and Southern Africa. A propensity score matching approach was applied to control for the influence of five factors (age, risk group, virus subtype, gender, and country) known to influence disease progression on causal observations. Fifty-two plasma proteins were assessed at two timepoints in the 1st year of infection. We independently confirmed factors known to influence disease progression such as the B*57 HLA Class I allele, and infecting virus Subtype. We demonstrated associations between circulating levels of MIP-1α and IL-17C, and the ability to control infection. IL-17C has not been described previously within the context of HIV control, making it an interesting target for future studies to understand HIV infection and transmission. An in-depth systems analysis is now underway to fully characterise host, viral and immunological factors contributing to control.
Collapse
Affiliation(s)
- Julia Makinde
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - Eunice W Nduati
- Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
| | - Anna Freni-Sterrantino
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom
| | - Claire Streatfield
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - Catherine Kibirige
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - Jama Dalel
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - S Lucas Black
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - Peter Hayes
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - Gladys Macharia
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - Jonathan Hare
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - Edward McGowan
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - Brian Abel
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - Deborah King
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | - Sarah Joseph
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| | | | - Eric Hunter
- Emory Vaccine Centre, Yerkes National Primate Research Centre, Emory University, Atlanta, GA, United States.,Zambia-Emory HIV Research Project, Lusaka, Zambia
| | - Eduard J Sanders
- Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
| | - Matt Price
- IAVI, New York, NY, United States.,Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States
| | - Jill Gilmour
- IAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom
| |
Collapse
|
26
|
King D, Hume PA, Clark T, Foskett A, Barnes MJ. Training injury incidence in an amateur women's rugby union team in New Zealand over two consecutive seasons. J Sci Med Sport 2020; 24:544-548. [PMID: 33243595 DOI: 10.1016/j.jsams.2020.11.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 11/03/2020] [Accepted: 11/04/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVES To describe the training injury incidence in amateur women's rugby union in New Zealand over two consecutive seasons. DESIGN A prospective cohort observational study METHODS: A total of 69 amateur women's rugby 15s team playerswere observed. Training exposure and training injury incidence were calculated. RESULTS The 38 training injuries resulted in a total injury incidence of 11.4 (8.3-15.6) per 1,000 training-hours. There were 12 injuries that resulted in a time-loss injury incidence of 3.6 (95% CI: 2.0-6.3) per 1,000 training-hours. Forwards recorded more total (RR: 1.8 [95% CI: 0.9-3.5]; p=0.0516) and time-loss (RR: 2.0 [95% CI: 0.6-6.6]; p=0.2482) injuries than Backs. The tackle was the most common injury cause for total (3.0 [95% CI: 1.6-5.6] per 1,000 training-hours.) injuries, but collisions (1.5 [95% CI: 0.6-3.6] per 1,000 training-hours.) with the ground or another person were the most common cause for time-loss injuries.The training injuries occurred most often to the lower limb and during the latter part of training sessions. These injuries were mostly minor in nature resulting in minimal time-loss away from training. DISCUSSION The time-loss injury incidence (3.6 per 1,000 training-hours.) for the amateur women's rugby 15s team players was higher than that reported for National (1.2 per 1,000 training-hours.) and Rugby World Cup for women (0.2 to 3.0 per 1,000 training-hours.) competitions. CONCLUSION The training injury incidence in amateur women's rugby union in New Zealand was higher than that reported for national and international rugby union injury incidences.
Collapse
Affiliation(s)
- D King
- School of Sport, Exercise and Nutrition, Massey University, New Zealand; School of Science and Technology, University of New England, Australia; Sports Performance Research Institute New Zealand (SPRINZ), Faculty of Health and Environmental Science, Auckland University of Technology, New Zealand; Traumatic Brain Injury Network (TBIN), Auckland University of Technology, New Zealand.
| | - P A Hume
- Sports Performance Research Institute New Zealand (SPRINZ), Faculty of Health and Environmental Science, Auckland University of Technology, New Zealand; National Institute of Stroke and Applied Neuroscience (NISAN), Faculty of Health and Environmental Science, Auckland University of Technology, New Zealand; Traumatic Brain Injury Network (TBIN), Auckland University of Technology, New Zealand
| | - T Clark
- International College of Management Sydney, Australia
| | - A Foskett
- School of Sport, Exercise and Nutrition, Massey University, New Zealand
| | - M J Barnes
- School of Sport, Exercise and Nutrition, Massey University, New Zealand
| |
Collapse
|
27
|
King D, Hume PA, Clark TN, Pearce AJ. Use of the King-Devick test for the identification of concussion in an amateur domestic women's rugby union team over two competition seasons in New Zealand. J Neurol Sci 2020; 418:117162. [PMID: 33017712 DOI: 10.1016/j.jns.2020.117162] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Revised: 09/01/2020] [Accepted: 09/26/2020] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To investigate the use of the King-Devick (K-D) test for sideline assessment of concussive injuries in a New Zealand amateur women's rugby union team. DESIGN Prospective cohort observational. METHODS All players were K-D tested during pre-season using a tablet (iPad; Apple Inc., Cupertino, CA). Differences in K-D scores and test-retest reliability were calculated for baseline test scores, baseline, and post-injury (concussion) sideline assessment and baseline and post-season testing scores for tests by year and as a combined score. RESULTS One training-related (0.3 per 1000 training-hrs) and nine match-related (16.1 per 1000 match-hrs) concussions were recorded. The K-D post-injury (concussion) sideline test score were significantly slower than established baseline (-4.4 [-5.8 to -3.4] s; χ2(1) = 42.2; p < 0.0001; t(9) = -4.0; p = 0.0029; d = -0.8). There was good-to-excellent reliability of the K-D test for baseline (ICC: 0.84 to 0.89), post-injury (concussion) sideline assessment (ICC: 0.82 to 0.97) and post-season evaluation (ICC: 0.79 to 0.83). DISCUSSION By utilising the baseline to post-injury (concussion) assessment comparisons, any player with a post-injury (concussion) assessment slowing of their K-D test time, regardless of whether the player has, or has not had a witnessed insult, should be withheld from any further participation until they are evaluated by a medical professional trained in the management of concussion. CONCLUSION This study has provided additional evidence to support the use of the K-D test as a frontline method of assessing concussion with good to excellent reliability of the test for baseline, side-line assessment and post-season evaluation.
Collapse
Affiliation(s)
- D King
- Sport Performance Research Institute New Zealand (SPRINZ), Faculty of Health and Environment Science, Auckland University of Technology, Auckland, New Zealand; School of Science and Technology, University of New England, Armidale, NSW, Australia; School of Sport, Exercise and Nutrition, Massey University, New Zealand.
| | - P A Hume
- School of Science and Technology, University of New England, Armidale, NSW, Australia; National Institute of Stroke and Applied Neuroscience (NISAN), Faculty of Health and Environment Science, Auckland University of Technology, Auckland, New Zealand
| | - T N Clark
- International College of Management Sydney, Manly, New South Wales, Australia
| | - A J Pearce
- College of Science, Health and Engineering, La Trobe University, Bundoora, Melbourne, Victoria, Australia
| |
Collapse
|
28
|
McKean D, Ather S, Gandhi A, Hubble T, Belci M, Tiberti S, Papanikitas J, Yanny S, King D, Hughes R, Meagher T, de Heredria LL. Pelvic MRI in spinal cord injury patients: incidence of muscle signal change and early heterotopic ossification. Spinal Cord 2020; 59:635-641. [PMID: 32873893 DOI: 10.1038/s41393-020-00539-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 08/15/2020] [Accepted: 08/17/2020] [Indexed: 11/09/2022]
Abstract
STUDY DESIGN Prospective observational study. OBJECTIVE To evaluate pelvic MRI muscle signal changes and their association with early heterotopic ossification (HO) in patients with spinal cord injuries. SETTING National Spinal Injuries Unit, Stoke Mandeville, UK. METHODS Forty patients were imaged with at least two interval magnetic resonance (MR) studies of the pelvis in the first 6 months following a spinal cord injury. Scans were reviewed and scored for heterotopic ossification, muscle signal change and extent of muscle involvement. RESULTS Muscle signal change was present in 28 (70%) on the initial MRI and 31 (77%) by the second study. Six patients developed MR changes of prodromal or immature heterotopic ossification (15%). No restricted diffusion was demonstrated and no patient developed mature HO. Patients developing MR changes of early HO were more likely to have grade 3 muscle changes. CONCLUSION Increased T2 muscle signal is common following cord injury, is frequently progressive in the subacute period and is associated with complete injury and early MR signs of heterotopic ossification.
Collapse
Affiliation(s)
- David McKean
- Department of Radiology, Stoke Mandeville Hospital, Buckingahmshire Healthcare NHS Trust, Aylesbury, UK.
| | - Sarim Ather
- Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, UK
| | - Amar Gandhi
- Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, UK
| | - Talia Hubble
- Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, UK
| | - Maurizio Belci
- National Spinal Injuries Centre, Stoke Mandeville Hospital, Buckingahmshire Healthcare NHS Trust, Aylesbury, UK
| | - Simone Tiberti
- National Spinal Injuries Centre, Stoke Mandeville Hospital, Buckingahmshire Healthcare NHS Trust, Aylesbury, UK
| | - Joseph Papanikitas
- Department of Radiology, Stoke Mandeville Hospital, Buckingahmshire Healthcare NHS Trust, Aylesbury, UK
| | - Sarah Yanny
- Department of Radiology, Stoke Mandeville Hospital, Buckingahmshire Healthcare NHS Trust, Aylesbury, UK
| | - Deborah King
- Department of Radiology, Stoke Mandeville Hospital, Buckingahmshire Healthcare NHS Trust, Aylesbury, UK
| | - Richard Hughes
- Department of Radiology, Stoke Mandeville Hospital, Buckingahmshire Healthcare NHS Trust, Aylesbury, UK
| | - Thomas Meagher
- Department of Radiology, Stoke Mandeville Hospital, Buckingahmshire Healthcare NHS Trust, Aylesbury, UK
| | - Luis Lopez de Heredria
- National Spinal Injuries Centre, Stoke Mandeville Hospital, Buckingahmshire Healthcare NHS Trust, Aylesbury, UK
| |
Collapse
|
29
|
Macharia GN, Yue L, Staller E, Dilernia D, Wilkins D, Song H, McGowan E, King D, Fast P, Imami N, Price MA, Sanders EJ, Hunter E, Gilmour J. Infection with multiple HIV-1 founder variants is associated with lower viral replicative capacity, faster CD4+ T cell decline and increased immune activation during acute infection. PLoS Pathog 2020; 16:e1008853. [PMID: 32886726 PMCID: PMC7498102 DOI: 10.1371/journal.ppat.1008853] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 09/17/2020] [Accepted: 08/03/2020] [Indexed: 02/07/2023] Open
Abstract
HIV-1 transmission is associated with a severe bottleneck in which a limited number of variants from a pool of genetically diverse quasispecies establishes infection. The IAVI protocol C cohort of discordant couples, female sex workers, other heterosexuals and men who have sex with men (MSM) present varying risks of HIV infection, diverse HIV-1 subtypes and represent a unique opportunity to characterize transmitted/founder viruses (TF) where disease outcome is known. To identify the TF, the HIV-1 repertoire of 38 MSM participants' samples was sequenced close to transmission (median 21 days post infection, IQR 18-41) and assessment of multivariant infection done. Patient derived gag genes were cloned into an NL4.3 provirus to generate chimeric viruses which were characterized for replicative capacity (RC). Finally, an evaluation of how the TF virus predicted disease progression and modified the immune response at both acute and chronic HIV-1 infection was done. There was higher prevalence of multivariant infection compared with previously described heterosexual cohorts. A link was identified between multivariant infection and replicative capacity conferred by gag, whereby TF gag tended to be of lower replicative capacity in multivariant infection (p = 0.02) suggesting an overall lowering of fitness requirements during infection with multiple variants. Notwithstanding, multivariant infection was associated with rapid CD4+ T cell decline and perturbances in the CD4+ T cell and B cell compartments compared to single variant infection, which were reversible upon control of viremia. Strategies aimed at identifying and mitigating multivariant infection could contribute toward improving HIV-1 prognosis and this may involve strategies that tighten the stringency of the transmission bottleneck such as treatment of STI. Furthermore, the sequences and chimeric viruses help with TF based experimental vaccine immunogen design and can be used in functional assays to probe effective immune responses against TF.
Collapse
Affiliation(s)
- Gladys N. Macharia
- Department of Medicine, Imperial College London, London, United Kingdom
- IAVI Human Immunology Laboratory, London, United Kingdom
| | - Ling Yue
- Emory Vaccine Centre, Yerkes National Primate Research Centre, Emory University, Atlanta, GA, United States of America
| | - Ecco Staller
- Department of Medicine, Imperial College London, London, United Kingdom
- IAVI Human Immunology Laboratory, London, United Kingdom
| | - Dario Dilernia
- Emory Vaccine Centre, Yerkes National Primate Research Centre, Emory University, Atlanta, GA, United States of America
| | - Daniel Wilkins
- Emory Vaccine Centre, Yerkes National Primate Research Centre, Emory University, Atlanta, GA, United States of America
| | - Heeyah Song
- Emory Vaccine Centre, Yerkes National Primate Research Centre, Emory University, Atlanta, GA, United States of America
| | - Edward McGowan
- Department of Medicine, Imperial College London, London, United Kingdom
- IAVI Human Immunology Laboratory, London, United Kingdom
| | - Deborah King
- Department of Medicine, Imperial College London, London, United Kingdom
- IAVI Human Immunology Laboratory, London, United Kingdom
| | - Pat Fast
- IAVI, New York, NY, United States of America
| | - Nesrina Imami
- Department of Medicine, Imperial College London, London, United Kingdom
| | - Matthew A. Price
- IAVI, New York, NY, United States of America
- Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, United States of America
| | - Eduard J. Sanders
- Kenya Medical Research Institute-Wellcome Trust, Kilifi, Kenya
- Nuffield Department of Clinical Medicine, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Headington, United Kingdom
| | - Eric Hunter
- Emory Vaccine Centre, Yerkes National Primate Research Centre, Emory University, Atlanta, GA, United States of America
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States of America
| | - Jill Gilmour
- Department of Medicine, Imperial College London, London, United Kingdom
- IAVI Human Immunology Laboratory, London, United Kingdom
| |
Collapse
|
30
|
Boum Y, Juan-Giner A, Hitchings M, Soumah A, Strecker T, Sadjo M, Cuthbertson H, Hayes P, Tchaton M, Jemmy JP, Clarck C, King D, Faga EM, Becker S, Halis B, Gunnstein N, Carroll M, Røttingen JA, Kondé MK, Doumbia M, Henao-Restrepo AM, Kieny MP, Cisse M, Draguez B, Grais RF. Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea. Vaccine 2020; 38:4877-4884. [PMID: 32499066 PMCID: PMC7306162 DOI: 10.1016/j.vaccine.2020.04.066] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2020] [Accepted: 04/26/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND As part of a Phase III trial with the Ebola vaccine rVSVΔG-ZEBOV-GP in Guinea, we invited frontline workers (FLWs) to participate in a sub-study to provide additional information on the immunogenicity of the vaccine. METHODS We conducted an open-label, non-randomized, single-arm immunogenicity evaluation of one dose of rVSVΔG-ZEBOV-GP among healthy FLWs in Guinea. FLWs who refused vaccination were offered to participate as a control group. We followed participants for 84 days with a subset followed-up for 180 days. The primary endpoint was immune response, as measured by ELISA for ZEBOV-glycoprotein-specific antibodies (ELISA-GP) at 28 days. We also conducted neutralization, whole virion ELISA and enzyme-linked immunospot (ELISPOT) assay for cellular response. RESULTS A total of 1172 participants received one dose of vaccine and were followed-up for 84 days, among them 114 participants were followed-up for 180 days. Additionally, 99 participants were included in the control group and followed up for 180 days. Overall, 86.4% (95% CI 84.1-88.4) of vaccinated participants seroresponded at 28 days post-vaccination (ELISA- GP) with 65% of these seroresponding at 14 days post-vaccination. Among those who seroresponded at 28 days, 90.7% (95% CI 82.0-95.4) were still seropositive at 180 days. The proportion of seropositivity in the unvaccinated group was 0.0% (95% CI 0.0-3.8) at 28 days and 5.4% (95% CI 2.1-13.1) at 180 days post-vaccination. We found weak correlation between ELISA-GP and neutralization at baseline but significant pairwise correlation at 28 days post-vaccination. Among samples analysed for cellular response, only 1 (2.2%) exhibited responses towards the Zaire Ebola glycoprotein (Ebola GP ≥ 10) at baseline, 10 (13.5%) at day 28 post-vaccination and 27 (48.2%) at Day 180. CONCLUSIONS We found one dose of rVSVΔG-ZEBOV-GP to be highly immunogenic at 28- and 180-days post vaccination among frontline workers in Guinea. We also found a cellular response that increased with time.
Collapse
Affiliation(s)
| | | | - Matt Hitchings
- Center for Communicable Disease Dynamics and Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | | | - Thomas Strecker
- Institute of Virology, Philipps University, Marburg, Germany
| | - Mariama Sadjo
- Centre Hospital-Universitaire de Donka, Conakry, Guinea
| | | | - Peter Hayes
- Division of Medicine, Department of Infectious Diseases, Imperial College London, UK
| | | | - Jean-Paul Jemmy
- Médecins Sans Frontières-Operational Center Belgium, Brussels, Belgium
| | - Carolyn Clarck
- Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway
| | - Deborah King
- Division of Medicine, Department of Infectious Diseases, Imperial College London, UK
| | | | - Stephan Becker
- Institute of Virology, Philipps University, Marburg, Germany
| | - Bassam Halis
- Public Health England, National Infection Service, Porton Down, UK
| | - Norheim Gunnstein
- Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway
| | - Miles Carroll
- Public Health England, National Infection Service, Porton Down, UK
| | - John-Arne Røttingen
- Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway; Department of Health and Society, University of Oslo, Norway; Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA; Coalition for Epidemic Preparedness Innovations, Care of Norwegian Institute of Public Health, Oslo, Norway; Research Council of Norway, Oslo, Norway
| | - Mandy Kader Kondé
- Center of Excellence for Training, Research On Malaria & Priority Diseases In Guinea, Conakry, Guinea
| | | | | | | | - Mohamed Cisse
- Centre Hospital-Universitaire de Donka, Conakry, Guinea
| | - Bertrand Draguez
- Médecins Sans Frontières-Operational Center Belgium, Brussels, Belgium
| | | |
Collapse
|
31
|
Cruz-Torres R, Nguyen D, Hauenstein F, Schmidt A, Li S, Abrams D, Albataineh H, Alsalmi S, Androic D, Aniol K, Armstrong W, Arrington J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Beck A, Bellini V, Benmokhtar F, Bhatt H, Bhetuwal D, Biswas D, Blyth D, Boeglin W, Bulumulla D, Camsonne A, Castellanos J, Chen JP, Cohen EO, Covrig S, Craycraft K, Dongwi B, Duer M, Duran B, Dutta D, Fuchey E, Gal C, Gautam TN, Gilad S, Gnanvo K, Gogami T, Golak J, Gomez J, Gu C, Habarakada A, Hague T, Hansen O, Hattawy M, Hen O, Higinbotham DW, Hughes E, Hyde C, Ibrahim H, Jian S, Joosten S, Kamada H, Karki A, Karki B, Katramatou AT, Keppel C, Khachatryan M, Khachatryan V, Khanal A, King D, King P, Korover I, Kutz T, Lashley-Colthirst N, Laskaris G, Li W, Liu H, Liyanage N, Markowitz P, McClellan RE, Meekins D, Mey-Tal Beck S, Meziani ZE, Michaels R, Mihovilovič M, Nelyubin V, Nuruzzaman N, Nycz M, Obrecht R, Olson M, Ou L, Owen V, Pandey B, Pandey V, Papadopoulou A, Park S, Patsyuk M, Paul S, Petratos GG, Piasetzky E, Pomatsalyuk R, Premathilake S, Puckett AJR, Punjabi V, Ransome R, Rashad MNH, Reimer PE, Riordan S, Roche J, Sargsian M, Santiesteban N, Sawatzky B, Segarra EP, Schmookler B, Shahinyan A, Širca S, Skibiński R, Sparveris N, Su T, Suleiman R, Szumila-Vance H, Tadepalli AS, Tang L, Tireman W, Topolnicki K, Tortorici F, Urciuoli G, Weinstein LB, Witała H, Wojtsekhowski B, Wood S, Ye ZH, Ye ZY, Zhang J. Probing Few-Body Nuclear Dynamics via ^{3}H and ^{3}He (e,e^{'}p)pn Cross-Section Measurements. Phys Rev Lett 2020; 124:212501. [PMID: 32530643 DOI: 10.1103/physrevlett.124.212501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 03/12/2020] [Accepted: 04/30/2020] [Indexed: 06/11/2023]
Abstract
We report the first measurement of the (e,e^{'}p) three-body breakup reaction cross sections in helium-3 (^{3}He) and tritium (^{3}H) at large momentum transfer [⟨Q^{2}⟩≈1.9 (GeV/c)^{2}] and x_{B}>1 kinematics, where the cross section should be sensitive to quasielastic (QE) scattering from single nucleons. The data cover missing momenta 40≤p_{miss}≤500 MeV/c that, in the QE limit with no rescattering, equals the initial momentum of the probed nucleon. The measured cross sections are compared with state-of-the-art ab initio calculations. Overall good agreement, within ±20%, is observed between data and calculations for the full p_{miss} range for ^{3}H and for 100≤p_{miss}≤350 MeV/c for ^{3}He. Including the effects of rescattering of the outgoing nucleon improves agreement with the data at p_{miss}>250 MeV/c and suggests contributions from charge-exchange (SCX) rescattering. The isoscalar sum of ^{3}He plus ^{3}H, which is largely insensitive to SCX, is described by calculations to within the accuracy of the data over the entire p_{miss} range. This validates current models of the ground state of the three-nucleon system up to very high initial nucleon momenta of 500 MeV/c.
Collapse
Affiliation(s)
- R Cruz-Torres
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - D Nguyen
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
- University of Education, Hue University, Hue City, Vietnam
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Schmidt
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - D Abrams
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Albataineh
- Texas A & M University, Kingsville, Texas 78363, USA
| | - S Alsalmi
- King Saud University, Riyadh 11451, Kingdom of Saudi Arabia
| | - D Androic
- University of Zagreb, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, California 90032, USA
| | - W Armstrong
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Arrington
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Ayerbe Gayoso
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37966, USA
| | - S Barcus
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - A Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - V Bellini
- INFN Sezione di Catania, 95123 Catania, Italy
| | - F Benmokhtar
- Duquesne University, Pittsburgh, Pennsylvania 15282, USA
| | - H Bhatt
- Mississippi State University, Mississippi 39762, USA
| | - D Bhetuwal
- Mississippi State University, Mississippi 39762, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - D Blyth
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - W Boeglin
- Florida International University, Miami, Florida 33199, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Camsonne
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - J Castellanos
- Florida International University, Miami, Florida 33199, USA
| | - J-P Chen
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - E O Cohen
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - S Covrig
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - K Craycraft
- University of Tennessee, Knoxville, Tennessee 37966, USA
| | - B Dongwi
- Hampton University, Hampton, Virginia 23669, USA
| | - M Duer
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Dutta
- Mississippi State University, Mississippi 39762, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T N Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - S Gilad
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Gogami
- Tohoku University, Sendai, Miyagi 980-8577, Japan
| | - J Golak
- M. Smoluchowski Institute of Physics, Jagiellonian University, PL-30348 Kraków, Poland
| | - J Gomez
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Habarakada
- Hampton University, Hampton, Virginia 23669, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - O Hansen
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Hattawy
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - O Hen
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | | | - E Hughes
- Columbia University, New York, New York 10027, USA
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, 12613 Cairo, Egypt
| | - S Jian
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Joosten
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - H Kamada
- Department of Physics, Faculty of Engineering, Kyushu Institute of Technology, Kitakyushu 804-8550, Japan
| | - A Karki
- Mississippi State University, Mississippi 39762, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | | | - C Keppel
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Khachatryan
- Stony Brook, State University of New York, New York 11794, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - D King
- Syracuse University, Syracuse, New York 13244, USA
| | - P King
- Ohio University, Athens, Ohio 45701, USA
| | - I Korover
- Nuclear Research Center-Negev, Beer-Sheva, Israel
| | - T Kutz
- Stony Brook, State University of New York, New York 11794, USA
| | | | - G Laskaris
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - W Li
- University of Regina, Regina, SK S4S 0A2, Canada
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - N Liyanage
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | | | - D Meekins
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - S Mey-Tal Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Z-E Meziani
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
- Columbia University, New York, New York 10027, USA
| | - R Michaels
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Mihovilovič
- University of Ljubljana, 1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, Jožef Stefan Institute, Ljubljana, Slovenia
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, DE-55128 Mainz, Germany
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - R Obrecht
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Olson
- Saint Norbert College, De Pere, Wisconsin 54115, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - V Owen
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - V Pandey
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - A Papadopoulou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - M Patsyuk
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Paul
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | | | - E Piasetzky
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - R Pomatsalyuk
- Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - S Premathilake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R Ransome
- Rutgers University, New Brunswick, New Jersey 08901, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - S Riordan
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - M Sargsian
- Florida International University, Miami, Florida 33199, USA
| | - N Santiesteban
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - B Sawatzky
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - E P Segarra
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Shahinyan
- Yerevan Physics Institute, 0036 Yerevan, Armenia
| | - S Širca
- University of Ljubljana, 1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, Jožef Stefan Institute, SI-1000, Ljubljana, Slovenia
| | - R Skibiński
- M. Smoluchowski Institute of Physics, Jagiellonian University, PL-30348 Kraków, Poland
| | - N Sparveris
- Columbia University, New York, New York 10027, USA
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - R Suleiman
- Jefferson Lab, Newport News, Virginia 23606, USA
| | | | - A S Tadepalli
- Rutgers University, New Brunswick, New Jersey 08901, USA
| | - L Tang
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - W Tireman
- Northern Michigan University, Marquette, Michigan 49855, USA
| | - K Topolnicki
- M. Smoluchowski Institute of Physics, Jagiellonian University, PL-30348 Kraków, Poland
| | - F Tortorici
- INFN Sezione di Catania, 95123 Catania, Italy
| | | | - L B Weinstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Witała
- M. Smoluchowski Institute of Physics, Jagiellonian University, PL-30348 Kraków, Poland
| | | | - S Wood
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - Z H Ye
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - Z Y Ye
- University of Illinois-Chicago, Chicago, Illinois 60607, USA
| | - J Zhang
- Stony Brook, State University of New York, New York 11794, USA
| |
Collapse
|
32
|
King D, Platek M, Whelan M, Bampton T. Perception of Galactagogue Usage in Stimulating Breast Milk Production in Breastfeeding Mothers: A Qualitative Research Study. J Acad Nutr Diet 2019. [DOI: 10.1016/j.jand.2019.08.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Piron L, Challis C, Felton R, King D, Lennholm M, Lomas P, Piron C, Rimini F, Valcarcel D. The dud detector: An empirically-based real-time algorithm to save neutron and T budgets during JET DT operation. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.02.077] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
34
|
Bachanek-Bankowska K, Di Nardo A, Wadsworth J, King D, Knowles N. A47 Reconstructing the evolutionary history of pandemic foot-and-mouth disease viruses: The impact of recombination within the emerging O/ME-SA/Ind-2001 lineage. Virus Evol 2019. [PMCID: PMC6735776 DOI: 10.1093/ve/vez002.046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Foot-and-mouth disease (FMD) is a highly contagious disease of livestock affecting animal production and trade throughout Asia and Africa. Understanding FMD virus (FMDV) global movements and evolution can help to reconstruct the disease spread between endemic regions and predict the risks of incursion into FMD-free countries. Global expansion of a single FMDV lineage is rare but can result in severe economic consequences. Using extensive sequence data, we have reconstructed the global space-time transmission history of the O/ME-SA/Ind-2001 lineage (which normally circulates in the Indian sub-continent) providing evidence of at least fifteen independent escapes during 2013–7 that have led to outbreaks in North Africa, the Middle East, Southeast Asia, and the Far East and the FMD-free islands of Mauritius. We demonstrated that sequence heterogeneity of this emerging FMDV lineage is accommodated within two co-evolving divergent sublineages, and that recombination by exchange of capsid-coding sequences can impact upon the reconstructed evolutionary histories. Thus, we recommend that only sequences encoding the outer capsid proteins should be used for broad-scale phylogeographical reconstruction. These data emphasize the importance of the Indian subcontinent as a source of FMDV that can spread across large distances and illustrates the impact of FMDV genome recombination on FMDV molecular epidemiology.
Collapse
Affiliation(s)
| | - A Di Nardo
- The Pirbright Institute, Pirbright, Woking, Surrey, UK
| | - J Wadsworth
- The Pirbright Institute, Pirbright, Woking, Surrey, UK
| | - D King
- The Pirbright Institute, Pirbright, Woking, Surrey, UK
| | - N Knowles
- The Pirbright Institute, Pirbright, Woking, Surrey, UK
| |
Collapse
|
35
|
Affiliation(s)
- D King
- Liver Unit, Queen Elizabeth University Hospital Birmingham, Birmingham, UK
| | - M J Armstrong
- Liver Unit, Queen Elizabeth University Hospital Birmingham, Birmingham, UK
| |
Collapse
|
36
|
Cohen V, Linderman S, Scarborough DM, King D, Diggin D, Oh LS. Screening for Injury Risk in Gymnasts: Examining the Sport Specificity of the Drop Vertical Jump. Med Sci Sports Exerc 2019. [DOI: 10.1249/01.mss.0000561305.12170.4f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
37
|
Kilembe W, Okech B, Nielsen L, Muturi-Kioi V, Jaoko W, Mutua G, Sanders E, Mpendo J, Gumbe A, Chinyenzi K, Bont JD, Kuipers H, Crook A, King D, Kaleebu P, Fast P, Hanke T. PO 8515 CAPACITY BUILDING IN PREPARATION FOR AN HIV VACCINE TRIAL: THE GLOBALLY RELEVANT AIDS VACCINE EUROPE-AFRICA TRIALS PARTNERSHIP (GREAT). BMJ Glob Health 2019. [DOI: 10.1136/bmjgh-2019-edc.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
BackgroundThe Globally Relevant AIDS Vaccine Europe-Africa Trials (GREAT) partnership is an EDCTP-funded project that aims to foster collaboration between institutions in Europe and sub-Saharan Africa to build capacity among African clinical research centres (CRCs) for the design and conduct of HIV-1 vaccine efficacy trials.MethodsIn January 2017, the University of Oxford (UOXF) and five CRCs in Kenya, Uganda and Zambia were awarded a 5 year grant for capacity building and to support conduct of an HIV-1 vaccine trial in different high-risk populations across Africa using cross-clade (conserved protein regions) T-cell vaccines. UOXF and CRCs embarked on activities to strengthen capacity of the CRCs for future efficacy trials. This included training, community engagement, cohort preparation and infrastructure upgrade.ResultsIn the first year, the African investigators at the CRCs collaborated on the development of a protocol aimed at assessing the safety and immunogenicity of the tHIVconsvX vaccines. In preparation for the planned vaccine trial, infrastructure upgrades were prioritised at all partner sites and this included building laboratory space and procurement of appropriate laboratory equipment. Planned infrastructure upgrades will also ensure that high-risk populations can be safely and confidentially included in HIV prevention clinical trials. Systematic community engagement was implemented at all sites, training in GCP/GCLP was provided and training is planned for nominated CRC staff to lead community engagement efforts.ConclusionImproved infrastructure and the provision of targeted training will enhance future trials and increase the capacities of CRCs and staff to conduct quality trials in previously hard-to-reach populations. Early collaboration between investigators from European and sub-Saharan African institutions, with equal responsibilities in the protocol development process, established a meaningful partnership. EDCTP funding also offers a unique opportunity for capacity building.
Collapse
|
38
|
Donohue MJ, King D, Pfaller S, Mistry JH. The sporadic nature of Legionella pneumophila, Legionella pneumophila Sg1 and Mycobacterium avium occurrence within residences and office buildings across 36 states in the United States. J Appl Microbiol 2019; 126:1568-1579. [PMID: 30891905 PMCID: PMC6850209 DOI: 10.1111/jam.14196] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Revised: 12/19/2018] [Accepted: 12/21/2018] [Indexed: 12/20/2022]
Abstract
Aim Premise plumbing may disseminate the bacteria Legionella pneumophila and Mycobacterium avium, the causative agents for legionellosis and pulmonary nontuberculous mycobacterium disease respectively. Methods and Results Using quantitative PCR, the occurrence and persistence of L. pneumophila, L. pneumophila serogroup (Sg)1 and M. avium were evaluated in drinking water samples from 108 cold water taps (residences: n = 43) and (office buildings: n = 65). Mycobacterium avium, L. pneumophila and L. pneumophila Sg1 were detected 45, 41 and 25% of all structures respectively. Two occurrence patterns were evaluated: sporadic (a single detection from the three samplings) and persistent (detections in two or more of the three samples). Conclusions The micro‐organism's occurrence was largely sporadic. Office buildings were prone to microbial persistence independent of building age and square footage. Microbial persistence at residences was observed in those older than 40 years for L. pneumophila and was rarely observed for M. avium. The microbial occurrence was evenly distributed between structure types but there were differences in density and persistence. Significance of and Impact of the Study The study is important because residences are often suspected to be the source when a case of disease is reported. These data demonstrate that this may not be the case for a sporadic incidence.
Collapse
Affiliation(s)
- M J Donohue
- National Exposure Research Laboratory, United States Environmental Protection Agency, Cincinnati, OH, USA
| | - D King
- National Exposure Research Laboratory, United States Environmental Protection Agency, Cincinnati, OH, USA
| | - S Pfaller
- National Exposure Research Laboratory, United States Environmental Protection Agency, Cincinnati, OH, USA
| | - J H Mistry
- Region 6, United States Environmental Protection Agency, Dallas, TX, USA
| |
Collapse
|
39
|
Cummins C, Welch M, King D, Shorter K, Murphy A. The association between external workloads and injury risk in professional rugby league players. J Sci Med Sport 2018. [DOI: 10.1016/j.jsams.2018.09.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
40
|
Hecimovich M, King D, Dempsey A, Gittins M, Murphy M. In situ use of the King-Devick Eye Tracking and changes seen with youth Sport Related Concussion: Saccadic and blinks counts. J Sci Med Sport 2018. [DOI: 10.1016/j.jsams.2018.09.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Najem MA, Tedder M, King D, Bernstein D, Trouncer R, Meehan C, Bidmead AM. In-vivo EPID dosimetry for IMRT and VMAT based on through-air predicted portal dose algorithm. Phys Med 2018; 52:143-153. [PMID: 30139603 DOI: 10.1016/j.ejmp.2018.07.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Revised: 07/02/2018] [Accepted: 07/24/2018] [Indexed: 11/28/2022] Open
Abstract
We have adapted the methodology of Berry et al. (2012) for Intensity Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) treatments at a fixed source to imager distance (SID) based on the manufacturer's through-air portal dose image prediction algorithm. In order to fix the SID a correction factor was introduced to account for the change in air gap between patient and imager. Commissioning data, collected with multiple field sizes, solid water thicknesses and air gaps, were acquired at 150 cm SID on the Varian aS1200 EPID. The method was verified using six IMRT and seven VMAT plans on up to three different phantoms. The method's sensitivity and accuracy were investigated by introducing errors. A global 3%/3 mm gamma was used to assess the differences between the predicted and measured portal dose images. The effect of a varying air gap on EPID signal was found to be significant - varying by up to 30% with field size, phantom thickness, and air gap. All IMRT plans passed the 3%/3 mm gamma criteria by more than 95% on the three phantoms. 23 of 24 arcs from the VMAT plans passed the 3%/3 mm gamma criteria by more than 95%. This method was found to be sensitive to a range of potential errors. The presented approach provides fast and accurate in-vivo EPID dosimetry for IMRT and VMAT treatments and can potentially replace many pre-treatment verifications.
Collapse
Affiliation(s)
- M A Najem
- Joint Department of Physics, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK.
| | - M Tedder
- Medical Physics Department, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK
| | - D King
- Joint Department of Physics, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
| | - D Bernstein
- Joint Department of Physics, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
| | - R Trouncer
- Joint Department of Physics, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
| | - C Meehan
- Joint Department of Physics, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
| | - A M Bidmead
- Joint Department of Physics, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
| |
Collapse
|
42
|
French JE, Gatti DM, Morgan DL, Kissling GE, Shockley KR, Knudsen GA, Shepard KG, Price HC, King D, Witt KL, Pedersen LC, Munger SC, Svenson KL, Churchill GA. Erratum: "Diversity Outbred Mice Identify Population-Based Exposure Thresholds and Genetic Factors that Influence Benzene-Induced Genotoxicity". Environ Health Perspect 2018; 126:069003. [PMID: 29957589 PMCID: PMC6084855 DOI: 10.1289/ehp3950] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Accepted: 05/24/2018] [Indexed: 06/08/2023]
Abstract
[This corrects the article DOI: http://dx.doi.org/10.1289/ehp.1408202.].
Collapse
|
43
|
Chernoff N, Hill DJ, Chorus I, Diggs DL, Huang H, King D, Lang JR, Le TT, Schmid JE, Travlos GS, Whitley EM, Wilson RE, Wood CR. Cylindrospermopsin toxicity in mice following a 90-d oral exposure. J Toxicol Environ Health A 2018; 81:549-566. [PMID: 29693504 PMCID: PMC6764423 DOI: 10.1080/15287394.2018.1460787] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Accepted: 02/26/2018] [Indexed: 05/19/2023]
Abstract
Cylindrospermopsin (CYN) is a toxin associated with numerous species of freshwater cyanobacteria throughout the world. It is postulated to have caused an episode of serious illnesses in Australia through treated drinking water, as well as lethal effects in livestock exposed to water from farm ponds. Toxicity included effects indicative of both hepatic and renal dysfunction. In humans, symptoms progressed from initial hepatomegaly, vomiting, and malaise to acidosis and hypokalemia, bloody diarrhea, and hyperemia in mucous membranes. Laboratory animal studies predominantly involved the intraperitoneal (i.p.) route of administration and confirmed this pattern of toxicity with changes in liver enzyme activities and histopathology consistent with hepatic injury and adverse renal effects. The aim of this study was designed to assess subchronic oral exposure (90 d) of purified CYN from 75 to 300 µg/kg/d in mouse. At the end of the dosing period, examinations of animals noted (1) elevated organ to body weight ratios of liver and kidney at all dose levels, (2) treatment-related increases in serum alanine aminotransferase (ALT) activity, (3) decreased blood urea nitrogen (BUN) and cholesterol concentrations in males, and (4) elevated monocyte counts in both genders. Histopathological alterations included hepatocellular hypertrophy and cord disruption in the liver, as well as renal cellular hypertrophy, tubule dilation, and cortical tubule lesions that were more prominent in males. A series of genes were differentially expressed including Bax (apoptosis), Rpl6 (tissue regeneration), Fabp4 (fatty acid metabolism), and Proc (blood coagulation). Males were more sensitive to many renal end points suggestive of toxicity. At the end of exposure, toxicity was noted at all dose levels, and the 75 µg/kg group exhibited significant effects in liver and kidney/body weight ratios, reduced BUN, increased serum monocytes, and multiple signs of histopathology indicating that a no-observed-adverse-effect level could not be determined for any dose level.
Collapse
Affiliation(s)
- N Chernoff
- a National Health and Environmental Effects Research Laboratory , US Environmental Protection Agency, Office of Research and Development , Research Triangle Park , NC , USA
| | - D J Hill
- a National Health and Environmental Effects Research Laboratory , US Environmental Protection Agency, Office of Research and Development , Research Triangle Park , NC , USA
| | - I Chorus
- b Division of Drinking-Water and Swimming-Pool Hygiene , Umweltbundesamt , Berlin , Germany
| | - D L Diggs
- c NHEERL , Oak Ridge Institute for Science and Education Internship/Research Participation Program at the US Environmental Protection Agency , Research Triangle Park , NC , USA
| | - H Huang
- d North Carolina State University , Raleigh , NC , USA
| | - D King
- e Cellular and Molecular Pathology Branch , National Institute of Environmental Health Sciences , Research Triangle Park , NC , USA
| | - J R Lang
- c NHEERL , Oak Ridge Institute for Science and Education Internship/Research Participation Program at the US Environmental Protection Agency , Research Triangle Park , NC , USA
| | - T-T Le
- c NHEERL , Oak Ridge Institute for Science and Education Internship/Research Participation Program at the US Environmental Protection Agency , Research Triangle Park , NC , USA
| | - J E Schmid
- a National Health and Environmental Effects Research Laboratory , US Environmental Protection Agency, Office of Research and Development , Research Triangle Park , NC , USA
| | - G S Travlos
- e Cellular and Molecular Pathology Branch , National Institute of Environmental Health Sciences , Research Triangle Park , NC , USA
| | - E M Whitley
- f Pathogenesis , LLC , Gainesville , FL , USA
| | - R E Wilson
- e Cellular and Molecular Pathology Branch , National Institute of Environmental Health Sciences , Research Triangle Park , NC , USA
| | - C R Wood
- a National Health and Environmental Effects Research Laboratory , US Environmental Protection Agency, Office of Research and Development , Research Triangle Park , NC , USA
| |
Collapse
|
44
|
Abstract
Elderly people have a greater need for domestic heating given the time they spend at home and the decline in the body thermoregulation that occurs with ageing. The use of domestic heating by 200 mentally competent newly admitted elderly in patients was evaluated by means of a questionnaire survey. Most patients (69%) were aware of the addition of value added tax (VAT) to their fuel bill and 31 % said they had reduced the amount of heating they use because of this. A third of patients (29.5%) said they had difficulty keeping warm prior to this admission. The majority of patients said they could not manage to keep warm in the winter without financial hardship. In addition, 29% said they had reduced the amount spent on food in order to pay for fuel bills. This study suggests that cold may contribute to hospital admissions in elderly patients. This should have implications for government spending and taxation policy on domestic heating.
Collapse
Affiliation(s)
- R Morgan
- Withington Hospital, Manchester, England
| | | | | |
Collapse
|
45
|
Kerry G, Gokani S, Ash J, Rasasingam D, Zargaran A, Mittal A, Mobasheri M, King D, Darzi A, Purkayastha S. The use of Digital Education for Patients on the Bariatric Surgery Pathway. Int J Surg 2017. [DOI: 10.1016/j.ijsu.2017.08.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
46
|
Henrikson NB, Chang E, Ulrich K, King D, Anderson ML. Communication with Physicians about Health Care Costs: Survey of an Insured Population. Perm J 2017; 21:16-070. [PMID: 28406786 DOI: 10.7812/tpp/16-070] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
CONTEXT Health care costs have increasingly shifted to patients, and financial distress caused by medical care has increased. Patients may wish to discuss costs with their clinicians. OBJECTIVE Describe patient preferences for communication about cost in the clinical setting. DESIGN Cross-sectional, self-administered survey of a stratified random sample of the population insured in an integrated health care system in Washington State. Our sampling frame was the entire membership aged 21 years or older. Sampling was stratified by sex and group practice enrollment. MAIN OUTCOME MEASURES Preference for discussing health care costs with one's physician. We conducted regression analyses to determine predictors of communication preference; potential predictors included demographic characteristics, financial burden, delay in seeking care because of cost, and socioeconomic variables. Survey responses were weighted to adjust for nonresponse and sampling. RESULTS Of 7200 invitations sent, 2200 survey responses were returned. Ninety-two percent wished to know their out-of-pocket costs before beginning treatment. Most respondents preferred their physician talk with them about out-of-pocket costs (81.4%) and expressed comfort with discussing costs with their physician (75.6%). Overall, 43.7% reported any delay in seeking care in the previous 12 months. One in 5 respondents (21.6%) reported family medical debt. Delay in seeking care was positively and independently associated with preferring to discuss costs with one's physician; current medical financial burden was not. CONCLUSION Patient preferences for communication about costs with physicians are high, and medical debt and delay in care-seeking are prevalent. Delay in care-seeking independently predicts cost communication preferences.
Collapse
Affiliation(s)
- Nora B Henrikson
- Research Associate at Kaiser Permanente Washington Health Research Institute, formerly Group Health Research Institute, in Seattle, WA.
| | - Eva Chang
- Research Public Health Analyst from the Division of Health Services and Social Policy at RTI International in Waltham, MA.
| | - Kevin Ulrich
- Director of the Survey Lab Research Center from the Division of the Social Sciences at the University of Chicago in IL.
| | - Deborah King
- Research Interventionist at Kaiser Permanente Washington Health Research Institute, formerly Group Health Research Institute, in Seattle, WA.
| | - Melissa L Anderson
- Senior Biostatistician at Kaiser Permanente Washington Health Research Institute, formerly Group Health Research Institute, in Seattle, WA.
| |
Collapse
|
47
|
Rossom RC, Simon G, Beck A, Richards J, Kirlin B, King D, Shulman L, Ludman E, Penfold R, Shortreed S, Whiteside U. Population-Based Outreach Versus Usual Care to Prevent Suicide Attempt: Study Protocol for a Randomized Clinical Trial. J Patient Cent Res Rev 2017. [DOI: 10.17294/2330-0698.1557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
48
|
Davison E, Pless Kaiser A, Wachen J, King L, King D, Moye J. LATER-ADULTHOOD TRAUMA REENGAGEMENT: FINDINGS FROM DISCUSSION GROUPS WITH OLDER COMBAT VETERANS. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- E.H. Davison
- National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts,
- Boston University School of Medicine, Boston, Massachusetts,
| | - A. Pless Kaiser
- National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts,
- Boston University School of Medicine, Boston, Massachusetts,
| | - J. Wachen
- National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts,
- Boston University School of Medicine, Boston, Massachusetts,
| | - L. King
- National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts,
- Boston University School of Medicine, Boston, Massachusetts,
| | - D. King
- National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts,
- Boston University School of Medicine, Boston, Massachusetts,
| | - J. Moye
- National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts,
- Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
49
|
Kratochvil S, McKay PF, Kopycinski JT, Bishop C, Hayes PJ, Muir L, Pinder CL, Cizmeci D, King D, Aldon Y, Wines BD, Hogarth PM, Chung AW, Kent SJ, Held K, Geldmacher C, Dally L, Santos NS, Cole T, Gilmour J, Fidler S, Shattock RJ. A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Front Immunol 2017; 8:595. [PMID: 28596770 PMCID: PMC5442169 DOI: 10.3389/fimmu.2017.00595] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Accepted: 05/05/2017] [Indexed: 12/24/2022] Open
Abstract
A key aspect to finding an efficacious human immunodeficiency virus (HIV) vaccine is the optimization of vaccine schedules that can mediate the efficient maturation of protective immune responses. In the present study, we investigated the effect of alternate booster regimens on the immune responses to a candidate HIV-1 clade C CN54gp140 envelope protein, which was coadministered with the TLR4-agonist glucopyranosyl lipid A-aqueous formulation. Twelve study participants received a common three-dose intramuscular priming series followed by a final booster at either 6 or 12 months. The two homologous prime-boost regimens were well tolerated and induced CN54gp140-specific responses that were observed in both the systemic and mucosal compartments. Levels of vaccine-induced IgG-subclass antibodies correlated significantly with FcγR engagement, and both vaccine regimens were associated with strikingly similar patterns in antibody titer and FcγR-binding profiles. In both groups, identical changes in the antigen (Ag)-specific IgG-subclass fingerprint, leading to a decrease in IgG1 and an increase in IgG4 levels, were modulated by booster injections. Here, the dissection of immune profiles further supports the notion that prime-boost strategies are essential for the induction of diverse Ag-specific HIV-1 responses. The results reported here clearly demonstrate that identical responses were effectively and safely induced by both vaccine regimens, indicating that an accelerated 6-month regimen could be employed for the rapid induction of immune responses against CN54gp140 with no apparent impact on the overall quality of the induced immune response. (This study has been registered at http://ClinicalTrials.gov under registration no. NCT01966900.)
Collapse
Affiliation(s)
| | | | | | - Cynthia Bishop
- Flow Cytometry Core Facility, Biomedical Research Centre, Guy's Hospital, London, UK
| | | | - Luke Muir
- Imperial College London, Medicine, London, UK
| | | | | | | | - Yoann Aldon
- Imperial College London, Medicine, London, UK
| | | | | | - Amy W Chung
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia
| | - Stephen J Kent
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, VIC, Australia.,Melbourne Sexual Health Centre, Department of Infectious Diseases, Alfred Health, Central Clinical School, Monash University, Melbourne, VIC, Australia
| | - Kathrin Held
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany
| | - Christof Geldmacher
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany
| | - Len Dally
- Emmes Corporation, Rockville, MD, USA
| | - Nelson S Santos
- NIHR/Wellcome Trust Imperial Clinical Research Facility Hammersmith Hospital, Imperial College London, London, UK
| | - Tom Cole
- NIHR/Wellcome Trust Imperial Clinical Research Facility Hammersmith Hospital, Imperial College London, London, UK
| | | | | | | |
Collapse
|
50
|
King D, Drill D, Fong A, Voorhees V, Kakar RS. Comparison of Lower Extremity Muscle Activity in Sliding Lunges versus Standard Lunges. Med Sci Sports Exerc 2017. [DOI: 10.1249/01.mss.0000519078.51163.5e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|